



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/03/15 (87) Date publication PCT/PCT Publication Date: 2018/09/20 (85) Entrée phase nationale/National Entry: 2019/09/13 (86) N° demande PCT/PCT Application No.: US 2018/022598 (87) N° publication PCT/PCT Publication No.: 2018/170239 (30) Priorités/Priorities: 2017/03/15 (US62/471,741); 2017/05/17 (US62/507,713)	(51) Cl.Int./Int.Cl. <i>C07K 14/47</i> (2006.01), <i>C12N 15/113</i> (2010.01), <i>C12N 15/85</i> (2006.01) (71) Demandeur/Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, US (72) Inventeurs/Inventors: CHERQUI, STEPHANIE, US; ADLER, ERIC, US; EVANS, SYLVIA, US (74) Agent: MBM INTELLECTUAL PROPERTY LAW LLP
---	---

(54) Titre : METHODES DE TRAITEMENT DE TROUBLES DU STOCKAGE LYSOSOMAL
(54) Title: METHODS OF TREATING LYSOSOMAL DISORDERS




FIG. 12D

(57) **Abrégé/Abstract:**
Provided herein are methods for treating a lysosomal transmembrane protein disease or disorder through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. Also provided are vectors containing the nucleic acid molecule.

- (51) International Patent Classification:

C07K 14/47 (2006.01) C12N 15/85 (2006.01)

C12N 15/113 (2010.01)
- (21) International Application Number:

PCT/US2018/022598
- (22) International Filing Date:

15 March 2018 (15.03.2018)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:

62/471,741 15 March 2017 (15.03.2017) US

62/507,713 17 May 2017 (17.05.2017) US
- (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 5th Floor, Oakland, California 94607 (US).
- (72) Inventors: CHERQUI, Stephanie; The Regents of the University of California, 9500 Gilman Drive, La Jolla, California 92093 (US). ADLER, Eric; The Regents of the University of California, 9500 Gilman Drive, La Jolla, California 92093 (US). EVANS, Sylvia; The Regents of the University of California, 9500 Gilman Drive, La Jolla, California 92093 (US).
- (74) Agent: NOVOM, Antony M. et al.; Wagenknecht IP Law Group PC, 12396 World Trade Drive, Suite 312, San Diego, California 92128 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF TREATING LYSOSOMAL DISORDERS




FIG. 12D

(57) Abstract: Provided herein are methods for treating a lysosomal transmembrane protein disease or disorder through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. Also provided are vectors containing the nucleic acid molecule.

WO 2018/170239 A1

METHODS OF TREATING LYSOSOMAL DISORDERS

CROSS REFERENCE TO RELATED APPLICATION(S)

[0001] This application claims the benefit of priority under 35 U.S.C. § 119(e) of US Serial No. 62/471,741, filed March 15, 2017, and of US Serial No. 62/507,713, filed May 17, 2017, the entire content of each of which is incorporated herein by reference.

GRANT INFORMATION

[0002] This invention was made with government support under Grant Nos. 2R01-DK090058 and PHS 7K23HL107755 awarded by the National Institutes of Health. The United States government has certain rights in the invention.

SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 15, 2018, is named 20378-201753_SL.txt and is 109 kilobytes in size.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

[0004] The invention relates generally to lysosomal diseases associated with dysfunctional transmembrane lysosomal proteins and more specifically to treatment of such diseases with hematopoietic stem and progenitor cell (HSPC) gene therapy.

BACKGROUND INFORMATION

[0005] Lysosomal membrane proteins act at several crucial steps of the lysosome life cycle, including lumen acidification, metabolite export, molecular motor recruitment and fusion with other organelles. Lysosomal storage diseases are a group of inherited metabolic disorders that result from defects in lysosomal function. Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective (for example, because of a mutation), the large molecules accumulate within the cell, eventually killing it.

[0006] Among the ~50 known lysosomal storage diseases, several are caused by lysosomal membrane protein dysfunction. One such lysosomal membrane protein disease is cystinosis, which is characterized by the abnormal accumulation of the amino acid cystine in all cells of

the body leading to multi-organ failure. Cystinosis is caused by mutations in the *CTNS* gene that codes for cystinosin, the lysosomal membrane-specific transporter for cystine. Intracellular metabolism of cystine, as it happens with all amino acids, requires its transport across the cell membrane. After degradation of endocytosed protein to cystine within lysosomes, it is normally transported to the cytosol. But if there is a defect in the carrier protein, cystine is accumulated in lysosomes. As cystine is highly insoluble, when its concentration in tissue lysosomes increase, its solubility is immediately exceeded and crystalline precipitates are formed in almost all organs and tissues. Another example is Danon disease, which is caused by mutations in the *LAMP-2* gene, a lysosomal transmembrane protein critical for autophagic flux.

[0007] To date, there are no known cures or preventative measures for such lysosomal diseases, with current therapies being directed to treating the associated symptoms. Thus, there is a need in the art for alternative or improved methods for treating lysosomal diseases/disorders.

SUMMARY OF THE INVENTION

[0008] Accordingly, in one aspect, the invention provides a method of treating a lysosomal transmembrane protein disease or disorder in a subject. The method includes introducing a corresponding functional human lysosomal transmembrane protein into hematopoietic stem and progenitor cells (HSPCs) of the subject, and transplanting the HSPCs into the subject, thereby treating the lysosomal transmembrane protein disease or disorder. Thus, when the lysosomal transmembrane protein disease or disorder is cystinosis, the corresponding functional human lysosomal transmembrane protein is cystinosin (CTNS); the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the corresponding functional human lysosomal transmembrane protein is sialin (SLC17A5); the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the corresponding functional human lysosomal transmembrane protein is LMBD1; the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the corresponding functional human lysosomal transmembrane protein is CLN7; the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the corresponding functional human lysosomal transmembrane protein is Battenin (CLN3); the lysosomal transmembrane protein disease or disorder is malignant infantile osteopetrosis, the corresponding functional human lysosomal transmembrane protein is CIC-7 or OSTM1; the lysosomal transmembrane protein disease or disorder is mucopolipidosis

IV, the corresponding functional human lysosomal transmembrane protein is TRPML-1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the corresponding functional human lysosomal transmembrane protein is HGSNAT; the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the corresponding functional human lysosomal transmembrane protein is NPC-1; and the lysosomal transmembrane protein disease or disorder is Danon disease, the corresponding functional human lysosomal transmembrane protein is LAMP2.

[0009] In various embodiments, the step of introducing may include contacting a vector comprising a polynucleotide encoding functional human lysosomal transmembrane protein and a functional promoter with the HSPCs and allowing expression of the functional human lysosomal transmembrane protein. In various embodiments, the lysosomal transmembrane protein disease or disorder is cystinosis and the functional human lysosomal transmembrane protein is CTNS. In various embodiments, the lysosomal transmembrane protein disease or disorder is Danon disease and the functional human lysosomal transmembrane protein is LAMP2. The LAMP2 may be an isoform selected from the group consisting of LAMP-2A, LAMP-2B, LAMP-2C. The subject may be a mammal, such as a human. In various embodiments, the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector. In various embodiments, the vector is a lentiviral vector. In various embodiments, the vector is an adenoviral vector. In various embodiments, the vector is an AAV vector. In various embodiments, the vector is a self-inactivating (SIN)-lentivirus vector, such as pCCL-CTNS or pCCL-LAMP2. In various embodiments, the step of introducing is performed *ex vivo*. In various embodiments, the HSPCs are isolated from the bone marrow of the subject.

[0010] In another aspect, the present invention provides an expression cassette comprising a promoter functionally linked to a transgene encoding a functional human lysosomal transmembrane protein selected from the group consisting of CTNS, SLC17A5, LMBRD1, CLN7, CLN3, CLC-7, OSTM1, TRPML1, HGSNAT, NPC1, and LAMP2. Also provided are a vector, such as a self-inactivating (SIN)-lentivirus vector, that includes a promoter functionally linked to a polynucleotide encoding a functional human lysosomal transmembrane protein selected from the group consisting of CTNS, SLC17A5, LMBRD1, CLN7, CLN3, CLC-7, OSTM1, TRPML1, HGSNAT, NPC1, and LAMP2. In various embodiments, the functional human lysosomal transmembrane protein is CTNS. In various embodiments, the functional human lysosomal transmembrane protein is LAMP2.

[0011] In another aspect, the present invention provides a method of treating or ameliorating a lysosomal protein disease or disorder in a subject. The method includes isolating hematopoietic stem and HSPCs cells from a subject's bone marrow, introducing a functional human lysosomal transmembrane gene into the HSPCs, wherein the gene encodes a protein corresponding to the lysosomal protein disease or disorder, and transplanting the HSPCs back into the subject, thereby treating or ameliorating the lysosomal protein disease or disorder. Thus, when the lysosomal transmembrane protein disease or disorder is cystinosis, the functional human lysosomal transmembrane gene is CTNS; the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the functional human lysosomal transmembrane gene is SLC17A5; the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the functional human lysosomal transmembrane gene is LMBRD1; the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is MFSD8; the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is CLN3; the lysosomal transmembrane protein disease or disorder is malignant infantile osteopoetrosis, the functional human lysosomal transmembrane gene is CLCN7 or OSTM1; the lysosomal transmembrane protein disease or disorder is mucopolidosis IV, the functional human lysosomal transmembrane gene is MCOLN1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the functional human lysosomal transmembrane gene is HGSNAT; the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the functional human lysosomal transmembrane gene is NPC1; and the lysosomal transmembrane protein disease or disorder is Danon disease, the functional human lysosomal transmembrane gene is LAMP2.

[0012] In various embodiments, the HSPCs are CD34⁺ cells. In various embodiments the lysosomal protein disease or disorder is cystinosis and the functional human lysosomal transmembrane gene is CTNS. In various embodiments, the lysosomal protein disease or disorder is Danon disease and the functional human lysosomal transmembrane gene is LAMP2. In various embodiments, the step of introducing the functional human CTNS gene into the HSPCs includes using a vector, such as a viral vector. In various embodiments, the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector. In various embodiments, the level of cystine in the eye, skin, leukocytes, parenchymal tissue or gastrointestinal tract of the subject is reduced following treatment. In various

embodiments, the dosage is about 1.0×10^6 to 5.0×10^6 cells/kg, such as 2.5×10^6 cells/kg, administered as a single dose.

[0013] The subject may be on cysteamine therapy, such as oral cysteamine therapy, prior to treatment. The dose administration may be intravenous. In various embodiments, cystine or cystine crystals are measure in the eye, skin, leukocytes, parenchymal tissue and/or gastrointestinal tract prior to and/or following treatment. In various embodiments, cystine or cystine crystals are measured in the eye prior to and/or following treatment. In various embodiments, cystine crystals are measured using *in vivo* confocal microscopy. In various embodiments, cystine levels may be measured prior to, during and/or following treatment. In various embodiments, cystine levels are measured using biological samples, such as blood, rectal biopsies, or buccal mucosa. In various embodiments, cystine levels are measured from rectal biopsies.

[0014] In another aspect, the present invention provides a method of treating or ameliorating a lysosomal protein disease or disorder in a subject. The method includes producing a functional human lysosomal transmembrane gene in the subject using gene editing. Thus, when the lysosomal transmembrane protein disease or disorder is cystinosis, the functional human lysosomal transmembrane gene is CTNS; the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the functional human lysosomal transmembrane gene is SLC17A5; the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the functional human lysosomal transmembrane gene is LMBRD1; the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is MFSD8; the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is CLN3; the lysosomal transmembrane protein disease or disorder is malignant infantile osteopoetrosis, the functional human lysosomal transmembrane gene is CLCN7 or OSTM1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis IV, the functional human lysosomal transmembrane gene is MCOLN1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the functional human lysosomal transmembrane gene is HGSNAT; the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the functional human lysosomal transmembrane gene is NPC1; and the lysosomal transmembrane protein disease or disorder is Danon disease, the functional human lysosomal transmembrane gene is LAMP2.

[0015] In another aspect, the the present invention provides a method of treating or ameliorating a lysosomal protein disease or disorder in a subject. The method includes contacting cells expressing a defective lysosomal transmembrane protein from the subject with a vector encoding a gene editing system that, when transfected into the cells, removes a trinucleotide extension mutation of the gene encoding the endogenous lysosomal transmembrane protein, thereby treating the lysosomal protein disease or disorder. Thus, when the lysosomal transmembrane protein disease or disorder is cystinosis, the lysosomal transmembrane protein is cystinosin (CTNS); the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the lysosomal transmembrane protein is sialin (SLC17A5); the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the lysosomal transmembrane protein is LMBD1; the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the lysosomal transmembrane protein is CLN7; the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the lysosomal transmembrane protein is Battenin (CLN3); the lysosomal transmembrane protein disease or disorder is malignant infantile osteopetrosis, the lysosomal transmembrane protein is ClC-7 or OSTM1; the lysosomal transmembrane protein disease or disorder is mucopolidosis IV, the lysosomal transmembrane protein is TRPML-1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the lysosomal transmembrane protein is HGSNAT; the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the lysosomal transmembrane protein is NPC-1; and the lysosomal transmembrane protein disease or disorder is Danon disease, the lysosomal transmembrane protein is LAMP2.

[0016] In various embodiments, the gene editing system is selected from the group consisting of CRISPR/Cas, zinc finger nucleases, engineered meganucleases, ARCUS, and transcription activator-like effector nucleases. In various embodiments, the step of contacting comprises administering to the subject an effective amount of the vector. In various embodiments, the step of contacting comprises obtaining a sample of cells from the subject, transfecting the gene editing system into the sample of cells, and thereafter, transplanting the transfected cells into the subject. In various embodiments, the sample of cells is selected from the group consisting of blood cells and HSPCs.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figures 1A-1D are pictorial diagrams showing histological analyses of kidney sections of 15 months old *Ctns*^{-/-} mice. Figures 1A and 1B show the results from hematoxylin

& eosin staining revealing severe anomalies in *Ctns*^{-/-} mice (Figure 1A) whereas HSC-transplanted *Ctns*^{-/-} mice exhibited only focal anomalies (Figure 1B). Figures 1C and 1D show the results of methylene blue staining revealed the presence of abundant cystine crystals in the kidney of the *Ctns*^{-/-} mice (Figure 1C) and very few in the treated *Ctns*^{-/-} mice (Figure 1D).

[0018] Figures 2A and 2B are pictorial and graphical diagrams showing cystine crystals in the cornea. Figure 2A shows lateral cornea IVCN representations of *Ctns*^{-/-} controls and LOW and HIGH HSC-transplanted mice. Figure 2B shows surface crystal quantification within each layer of the full IVCN cornea scans from both eyes of *Ctns*^{-/-} controls and transplanted (LOW and HIGH) mice. Error bars represent SEM (* $p < 0.05$, ** $p < 0.005$).

[0019] Figure 3 is a graphical diagram showing the results of a Thyroid study. Measure of cystine content (Left panel) and TSH level (Right panel) in *Ctns*^{-/-} mice compared to wild-type mice (WT) and *Ctns*^{-/-} mice transplanted with *Ctns*-expressing HSCs (grafted *Ctns*^{-/-}).

[0020] Figure 4 is a pictorial and graphical diagram showing the impact of HSC transplantation on gastrointestinal tract in *Ctns*^{-/-} mice. Left panel: Representative confocal picture of the colon: abundant GFP-expressing HSC-derived cells can be seen. Right panel: Cystine content in colon and intestine in HSC-transplanted *Ctns*^{-/-} mice compared to controls. * $p < 0.05$.

[0021] Figures 5A-5D are graphical and pictorial diagrams showing TNT-mediated transfer of cystinosin is the preferred mode of cross-correction. Figures 5A and 5B show histograms representing percent decrease in cystine content in DsRed-*Ctns*^{-/-} fibroblasts (recipient cells) when plated together with contact co-culture assays (Figure 5A) or separated by 1- μ m port transwell filters from transwell assays (Figure 5B) either GFP-MSCs or GFP-macrophages (donor cells) (N=4 replicates for each). Values are means $\pm$ standard deviations. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.005$. Figure 5C shows a confocal image of TNTs (arrowheads) extended from GFP-macrophages to DsRed-*Ctns*^{-/-} fibroblasts. Figure 5D shows representative frames from a confocal movie showing migration of cystinosin-GFP-contacting vesicles via TNTs from a CTNS-GFP-expressing macrophage towards *Ctns*^{-/-} fibroblasts (arrowheads). Bars: (Figure 5C) 30 μ m; (Figure 5D) 20 μ m.

[0022] Figures 6A-6C are pictorial diagrams showing TNT-mediated transfer *in vivo*, study of the kidney. Figure 6A shows confocal images of kidney from 8 month-old *Ctns*^{-/-} mice at 6 months post-transplantation with GFPWT HSPCs. GFP is in green and laminin in red. PTCs

(lumen, #) was labeled by Lotus Tetragonobus-lectin (LT) (blue). Figures 6A-a1, 6A-a2, and 6A a3 show that eGFP-expressing HSC-derived cells display numerous extensions. Arrowheads indicate TBL crossing. Apoptotic PTC (*). Figure 6A-a3 shows GFP-expressing green structures are located within PTCs. Figures 6B-6D show Z-stack confocal images of kidneys obtained from *Ctns*^{-/-} mice transplanted with DsRed-*Ctns*^{-/-} HSPCs (control, Figure 6B) or DsRed-*Ctns*^{-/-} HSPCs lentivirally transduced to express cystinosin-GFP and stained for phalloidin (Figure 6C). Cystinosin-GFP-containing vesicles are abundant in the cytoplasm of PTCs (Figure 6C). Figures 6B and 6C show nuclei that are stained in blue (DAPI). Scale bars: 5 μ m (Figure 6A), 10 μ m (Figures 6B and 6C).

[0023] Figure 7 is a pictorial diagram showing pCCL-CTNS lentivirus vector structure. SIN-LTR = Self-inactivating long terminal repeat; Ψ = Psi sequence; RRE = rev responsive element; cPPT = central polypurine tract; EFS = elongation factor 1 α short; *CTNS* cDNA = human *CTNS* cDNA; WPRE = woodchuck hepatitis post-transcriptional regulatory element.

[0024] Figures 8A-8D are graphical and pictorial diagrams showing cystine and cystine crystal quantification in male kidney. Figure 8A shows cystine content in non-treated *Ctns*^{-/-} mice (KO) compared with treated with pCCL-CTNS-HSCs. Figure 8B shows quantification of cystine crystals on kidney sections stained with methylene blue. Abundant cystine crystals were observed in kidney sections from nontreated *Ctns*^{-/-} mice (Figure 8C) in contrast to pCCLCTNS-treated mice (Figure 8D). Error bars are defined as Mean + SD, *P<0.05.

[0025] Figures 9A-9B are graphical diagrams showing the results from *in vivo* toxicology studies. Figures 9A-1 and 9A-2 show body weight of *Ctns*^{-/-} males (Figure 9A-1) and females treated (Figure 9A-2) with pCCL-CTNS-transduced HSCs and mock treated. Figure 9B shows cystine content in tissues of *Ctns*^{-/-} mice treated with pCCL-CTNS-transduced HSCs and mock treated.

[0026] Figures 10A-10E are pictorial diagrams showing LAMP2 expression in heart and skeletal muscle of WT-HSPC-transplant recipients. Figures 10A-10C are images showing LAMP2 expression in the hearts of WT (Figure 10A), KO (Figure 10B), and WT-HSPC transplanted showing LAMP2 expressing vesicles in cardiomyocytes adjacent to WT-GFP+ macrophages (Figure 10C). Arrows demonstrate RFP+ vacuoles. Western blots of heart (Figure 10D) and skeletal muscle (Figure 10E) lysates show near WT-level restoration of LAMP2 expression in mice recipient of WT-HSPC transplant.

[0027] Figure 11 is a graphical diagram showing the results of physiological assessment. Grip strength is rescued in mice recipients of WT-HSPC compared to KO (untreated) and KO-HSPC recipient mice. * $p < 0.05$ vs. WT; # $p < 0.05$ vs. WT-HSPC group.

[0028] Figures 12A-12D are pictorial and graphical diagrams showing rescue of increased autophagic flux following WT BMT. Figure 12A shows representative EM images of the hearts of WT, KO, WT-HSPC transplanted, and KO-HSPC transplanted mice. Figure 12B shows quantification of EM images demonstrating rescue of the accumulation of AVs in WT-HSPC mice to near WT levels. Figures 12C and 12D show Western blots and results demonstrating decreased LC-II/GAPDH levels in WT-HSPC transplanted mice vs. KO mice. * $p < 0.05$ vs. WT; # $p < 0.05$ vs. KO.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention is based, in part, on the finding that a self-inactivating (SIN)-lentivirus vector containing the encoding human cystinosis (CTNS) or LAMP-2 cDNA and a functional promoter can be used to *ex vivo* gene-corrected patients' autologous hematopoietic stem and progenitor cells (HSPCs), which can then be re-transplanted in the patients to repopulate their bone marrow, which is a reservoir of "healthy" cells for the rest of the life of the patients. These cells mobilize and integrate into the disease tissues, brain, muscle, heart, leading to their rescue. While autologous HSPCs are used in the illustrative examples herein, one of skill in the art would recognize that other HSPCs would be useful as well (e.g., allogeneic).

[0030] Before the present compositions and methods are described, it is to be understood that this invention is not limited to particular compositions, methods, and experimental conditions described, as such compositions, methods, and conditions may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only in the appended claims.

[0031] As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, references to "the method" includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.

[0032] The term “comprising,” which is used interchangeably with “including,” “containing,” or “characterized by,” is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.

[0033] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described.

[0034] The term “subject” or “host organism,” as used herein, refers to any individual or patient to which the subject methods are performed. Generally the subject is human, although as will be appreciated by those in the art, the subject may be an animal. Thus other animals, including mammals such as rodents (including mice, rats, hamsters and guinea pigs), cats, dogs, rabbits, farm animals including cows, horses, goats, sheep, pigs, etc., and primates (including monkeys, chimpanzees, orangutans and gorillas) are included within the definition of subject.

[0035] The term “biological sample,” refers to any sample taken from a participant, including but not limited to cells, blood, tissue, skin, urine, etc., or hair.

[0036] The term “buccal mucosa,” refers to the inside lining of the cheeks and floor of the mouth.

[0037] The term “therapeutically effective amount” or “effective amount” means the amount of a compound or pharmaceutical composition that elicits the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. Thus, the term “therapeutically effective amount” is used herein to denote any amount of a formulation that causes a substantial

improvement in a disease condition when applied to the affected areas repeatedly over a period of time. The amount varies with the condition being treated, the stage of advancement of the condition, and the type and concentration of formulation applied. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation. In the context of cystinosis, an example of a therapeutically effective amount of an agent, such as a population of hematopoietic stem cells transduced, gene-edited, or otherwise modified to express a human cystinosis transgene, is an amount sufficient to reduce the quantity of cystine (e.g., crystalline cystine) in the lysosomes of a cell in the patient, such as a cell in the kidney, liver, lung, spleen, muscle, brain, and/or heart.

[0038] A “dosage” or “dose” are defined to include a specified size, frequency, or exposure level are included within the definition.

[0039] A “therapeutic effect,” as used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described herein.

[0040] The terms “administration” or “administering” are defined to include an act of providing a compound or pharmaceutical composition of the invention to a subject in need of treatment. The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually orally or by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and infrasternal injection and infusion. The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the subject's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

[0041] If a viral vector specific for the cell type is not available, the vector can be modified to express a receptor (or ligand) specific for a ligand (or receptor) expressed on the target cell, or can be encapsulated within a liposome, which also can be modified to include such a ligand (or receptor). A peptide agent can be introduced into a cell by various methods, including, for example, by engineering the peptide to contain a protein transduction domain such as the human immunodeficiency virus TAT protein transduction domain, which can facilitate translocation of

the peptide into the cell. In addition, there are a variety of biomaterial-based technologies such as nano-cages and pharmacological delivery wafers (such as used in brain cancer chemotherapeutics) which may also be modified to accommodate this technology.

[0042] The viral vectors most commonly assessed for gene transfer are based on DNA-based adenoviruses (Ads) and adeno-associated viruses (AAVs) and RNA-based retroviruses and lentiviruses. Lentivirus vectors have been most commonly used to achieve chromosomal integration.

[0043] The term “parenchymal,” refers to the functional parts of an organ, which sometimes includes structural parts of the same and/or adjacent organ.

[0044] As used herein, the terms “reduce” and “inhibit” are used together because it is recognized that, in some cases, a decrease can be reduced below the level of detection of a particular assay. As such, it may not always be clear whether the expression level or activity is “reduced” below a level of detection of an assay, or is completely “inhibited.” Nevertheless, it will be clearly determinable, following a treatment according to the present methods.

[0045] As used herein, “treatment” or “treating” means to administer a composition to a subject or a system with an undesired condition. The condition can include a disease or disorder. “Prevention” or “preventing” means to administer a composition to a subject or a system at risk for the condition. The condition can include a predisposition to a disease or disorder. The effect of the administration of the composition to the subject (either treating and/or preventing) can be, but is not limited to, the cessation of one or more symptoms of the condition, a reduction or prevention of one or more symptoms of the condition, a reduction in the severity of the condition, the complete ablation of the condition, a stabilization or delay of the development or progression of a particular event or characteristic, or minimization of the chances that a particular event or characteristic will occur.

[0046] As used herein, the term “genetic modification” is used to refer to any manipulation of an organism’s genetic material in a way that does not occur under natural conditions. Methods of performing such manipulations are known to those of ordinary skill in the art and include, but are not limited to, techniques that make use of vectors for transforming cells with a nucleic acid sequence of interest. Included in the definition are various forms of gene editing in which DNA is inserted, deleted or replaced in the genome of a living organism using engineered nucleases, or “molecular scissors.” These nucleases create site-specific double-

strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations (*i.e.*, edits).

[0047] There are several families of engineered nucleases used in gene editing, for example, but not limited to, meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), the CRISPR-Cas system, and ARCUS. However, it should be understood that any known gene editing system utilizing engineered nucleases may be used in the methods described herein.

[0048] CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is an acronym for DNA loci that contain multiple, short, direct repetitions of base sequences. The prokaryotic CRISPR/Cas system has been adapted for use as gene editing (silencing, enhancing or changing specific genes) for use in eukaryotes (see, for example, Cong, Science, 15:339(6121):819-823 (2013) and Jinek, et al., Science, 337(6096):816-21 (2012)). By transfecting a cell with elements including a Cas gene and specifically designed CRISPRs, nucleic acid sequences can be cut and modified at any desired location. Methods of preparing compositions for use in genome editing using the CRISPR/Cas systems are described in detail in US Pub. No. 2016/0340661, US Pub. No. 20160340662, US Pub. No. 2016/0354487, US Pub. No. 2016/0355796, US Pub. No. 20160355797, and WO 2014/018423, which are specifically incorporated by reference herein in their entireties.

[0049] Thus, as used herein, “CRISPR system” refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a *tracr* (trans-activating CRISPR) sequence (*e.g.*, *tracr*RNA or an active partial *tracr*RNA), a *tracr*-mate sequence (encompassing a “direct repeat” and a *tracr*RNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a “spacer”, “guide RNA” or “gRNA” in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. One or more *tracr* mate sequences operably linked to a guide sequence (*e.g.*, direct repeat-spacer-direct repeat) can also be referred to as “pre-crRNA” (pre-CRISPR RNA) before processing or crRNA after processing by a nuclease.

[0050] In some embodiments, a *tracr*RNA and crRNA are linked and form a chimeric crRNA-*tracr*RNA hybrid where a mature crRNA is fused to a partial *tracr*RNA via a synthetic

stem loop to mimic the natural crRNA:tracrRNA duplex as described in Cong, Science, 15:339(6121):819-823 (2013) and Jinek, et al., Science, 337(6096):816-21 (2012)). A single fused crRNA-tracrRNA construct can also be referred to as a guide RNA or gRNA (or single-guide RNA (sgRNA)). Within an sgRNA, the crRNA portion can be identified as the 'target sequence' and the tracrRNA is often referred to as the 'scaffold'.

[0051] There are many resources available for helping practitioners determine suitable target sites once a desired DNA target sequence is identified. For example, numerous public resources, including a bioinformatically generated list of about 190,000 potential sgRNAs, targeting more than 40% of human exons, are available to aid practitioners in selecting target sites and designing the associate sgRNA to affect a nick or double strand break at the site. See also, crispr.u-psud.fr, a tool designed to help scientists find CRISPR targeting sites in a wide range of species and generate the appropriate crRNA sequences.

[0052] In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a target cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. While the specifics can be varied in different engineered CRISPR systems, the overall methodology is similar. A practitioner interested in using CRISPR technology to target a DNA sequence can insert a short DNA fragment containing the target sequence into a guide RNA expression plasmid. The sgRNA expression plasmid contains the target sequence (about 20 nucleotides), a form of the tracrRNA sequence (the scaffold) as well as a suitable promoter and necessary elements for proper processing in eukaryotic cells. Such vectors are commercially available (see, for example, Addgene). Many of the systems rely on custom, complementary oligos that are annealed to form a double stranded DNA and then cloned into the sgRNA expression plasmid. Co-expression of the sgRNA and the appropriate Cas enzyme from the same or separate plasmids in transfected cells results in a single or double strand break (depending of the activity of the Cas enzyme) at the desired target site.

[0053] Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be engineered to target specific desired DNA sequences and this enables zinc-finger nucleases to target unique sequences within complex genomes. By taking advantage of endogenous DNA repair machinery, these reagents can be used to precisely alter the genomes of higher organisms. The most common cleavage domain is the Type IIS enzyme FokI. FokI catalyzes

double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al. Proc., Natl. Acad. Sci. USA* 89 (1992):4275-4279; Li *et al. Proc. Natl. Acad. Sci. USA*, 90:2764-2768 (1993); Kim *et al. Proc. Natl. Acad. Sci. USA*. 91:883-887 (1994a); Kim *et al. J. Biol. Chem.* 269:31,978-31,982 (1994b), all of which are incorporated herein by reference. One or more of these enzymes (or enzymatically functional fragments thereof) can be used as a source of cleavage domains.

[0054] Transcription activator-like effector nucleases (TALENs) have an overall architecture similar to that of ZFNs, with the main difference being that the DNA-binding domain comes from TAL effector proteins, transcription factors from plant pathogenic bacteria. The DNA-binding domain of a TALEN is a tandem array of amino acid repeats, each about 34 residues long. The repeats are very similar to each other; typically they differ principally at two positions (amino acids 12 and 13, called the repeat variable diresidue, or RVD). Each RVD specifies preferential binding to one of the four possible nucleotides, meaning that each TALEN repeat binds to a single base pair, though the NN RVD is known to bind adenines in addition to guanine. TAL effector DNA binding is mechanistically less well understood than that of zinc-finger proteins, but their seemingly simpler code could prove very beneficial for engineered-nuclease design. TALENs also cleave as dimers, have relatively long target sequences (the shortest reported so far binds 13 nucleotides per monomer) and appear to have less stringent requirements than ZFNs for the length of the spacer between binding sites. Monomeric and dimeric TALENs can include more than 10, more than 14, more than 20, or more than 24 repeats. Methods of engineering TAL to bind to specific nucleic acids are described in Cermak, *et al, Nucl. Acids Res.* 1-11 (2011); US Published Application No. 2011/0145940, which discloses TAL effectors and methods of using them to modify DNA; Miller *et al. Nature Biotechnol* 29: 143 (2011) reported making TALENs for site-specific nuclease architecture by linking TAL truncation variants to the catalytic domain of FokI nuclease. The resulting TALENs were shown to induce gene modification in immortalized human cells. General design principles for TALE binding domains can be found in, for example, WO 2011/072246. Each of the foregoing references are incorporated herein by reference in their entireties.

[0055] The nuclease activity of the genome editing systems described herein cleave target DNA to produce single or double strand breaks in the target DNA. Double strand breaks can be repaired by the cell in one of two ways: non-homologous end joining, and homology-

directed repair. In non-homologous end joining (NHEJ), the double-strand breaks are repaired by direct ligation of the break ends to one another. As such, no new nucleic acid material is inserted into the site, although some nucleic acid material may be lost, resulting in a deletion. In homology-directed repair, a donor polynucleotide with homology to the cleaved target DNA sequence is used as a template for repair of the cleaved target DNA sequence, resulting in the transfer of genetic information from a donor polynucleotide to the target DNA. As such, new nucleic acid material can be inserted/copied into the site. Therefore, in some embodiments, the genome editing vector or composition optionally includes a donor polynucleotide. The modifications of the target DNA due to NHEJ and/or homology-directed repair can be used to induce gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, gene mutation, etc.

[0056] Accordingly, cleavage of DNA by the genome editing vector or composition can be used to delete nucleic acid material from a target DNA sequence by cleaving the target DNA sequence and allowing the cell to repair the sequence in the absence of an exogenously provided donor polynucleotide. Alternatively, if the genome editing composition includes a donor polynucleotide sequence that includes at least a segment with homology to the target DNA sequence, the methods can be used to add, *i.e.*, insert or replace, nucleic acid material to a target DNA sequence (*e.g.*, to “knock in” a nucleic acid that encodes for a protein, an siRNA, an miRNA, etc.), to add a tag (*e.g.*, 6xHis (SEQ ID NO: 27), a fluorescent protein (*e.g.*, a green fluorescent protein; a yellow fluorescent protein, etc.), hemagglutinin (HA), FLAG, etc.), to add a regulatory sequence to a gene (*e.g.*, promoter, polyadenylation signal, internal ribosome entry sequence (IRES), 2A peptide, start codon, stop codon, splice signal, localization signal, etc.), to modify a nucleic acid sequence (*e.g.*, introduce a mutation), and the like. As such, the compositions can be used to modify DNA in a site-specific, *i.e.*, “targeted” way, for example gene knock-out, gene knock-in, gene editing, gene tagging, etc., as used in, for example, gene therapy.

[0057] ARCUS is a genome editing platform derived from a natural genome editing enzyme referred to as a “homing endonuclease.” Homing endonucleases are site-specific DNA-cutting enzymes encoded in the genomes of many eukaryotic species that are able to precisely recognize long DNA sequences (12-40 base pairs). These non-destructive enzymes trigger gene conversion events that modify the genome in a very precise way, most frequently by the insertion of a new DNA sequence. Thus, the ARCUS genome editing platform relies upon engineered ARC nucleases, which are fully synthetic enzymes similar to a homing

endonuclease, but with improved specificity to recognize a DNA sequence within any target gene.

[0058] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

[0059] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, *e.g.*, hydroxyproline, α -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, *i.e.*, an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, *e.g.*, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (*e.g.*, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

[0060] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0061] As used herein, a “regulatory gene” or “regulatory sequence” is a nucleic acid sequence that encodes products (*e.g.*, transcription factors) that control the expression of other genes.

[0062] As used herein, a “protein coding sequence” or a sequence that encodes a particular protein or polypeptide, is a nucleic acid sequence that is transcribed into mRNA (in the case of DNA) and is translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' terminus (N-terminus) and a translation stop

nonsense codon at the 3' terminus (C-terminus). A coding sequence can include, but is not limited to, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic DNA, and synthetic nucleic acids. A transcription termination sequence will usually be located 3' to the coding sequence.

[0063] As used herein, a “promoter” is defined as a regulatory DNA sequence generally located upstream of a gene that mediates the initiation of transcription by directing RNA polymerase to bind to DNA and initiating RNA synthesis. A promoter can be a constitutively active promoter (*i.e.*, a promoter that is constitutively in an active/"ON" state), it may be an inducible promoter (*i.e.*, a promoter whose state, active/"ON" or inactive/"OFF", is controlled by an external stimulus, *e.g.*, the presence of a particular compound or protein), it may be a spatially restricted promoter (*i.e.*, transcriptional control element, enhancer, etc.)(*e.g.*, tissue specific promoter, cell type specific promoter, etc.), and it may be a temporally restricted promoter (*i.e.*, the promoter is in the "ON" state or "OFF" state during specific stages of embryonic development or during specific stages of a biological process. Thus, in various embodiments, the promoter may be a stem cell-specific promoter that drives transgene expression. For example, constitutive promoters of different strengths can be used. Expression vectors and plasmids in accordance with the present invention may include one or more constitutive promoters, such as viral promoters or promoters from mammalian genes that are generally active in promoting transcription. Exemplary promoters include, but are not limited to, human Elongation Factor 1 alpha promoter (EFS), SV40 early promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, an endogenous cellular promoter that is heterologous to the gene of interest, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), a Rous sarcoma virus (RSV) promoter, synthetic promoters, hybrid promoters, and the like

[0064] As used herein, the term “gene” means the deoxyribonucleotide sequences comprising the coding region of a structural gene. A “gene” may also include non-translated sequences located adjacent to the coding region on both the 5' and 3' ends such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences. The term “gene” encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene

contains the coding region interrupted with non-coding sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene which are transcribed into heterogenous nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

[0065] As used herein, the terms “functionally linked” and “operably linked” are used interchangeably and refer to a functional relationship between two or more DNA segments, in particular gene sequences to be expressed and those sequences controlling their expression. For example, a promoter/enhancer sequence, including any combination of cis-acting transcriptional control elements is operably linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Promoter regulatory sequences that are operably linked to the transcribed gene sequence are physically contiguous to the transcribed sequence.

[0066] “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

[0067] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters,

adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

[0068] The term “antibody” as used herein refers to polyclonal and monoclonal antibodies and fragments thereof, and immunologic binding equivalents thereof. The term “antibody” refers to a homogeneous molecular entity, or a mixture such as a polyclonal serum product made up of a plurality of different molecular entities, and broadly encompasses naturally-occurring forms of antibodies (for example, IgG, IgA, IgM, IgE) and recombinant antibodies such as single-chain antibodies, chimeric and humanized antibodies and multi-specific antibodies. The term “antibody” also refers to fragments and derivatives of all of the foregoing, and may further comprise any modified or derivatized variants thereof that retains the ability to specifically bind an epitope. Antibody derivatives may comprise a protein or chemical moiety conjugated to an antibody. A monoclonal antibody is capable of selectively binding to a target antigen or epitope. Antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, camelized antibodies, single chain antibodies (scFvs), Fab fragments, F(ab')₂ fragments, disulfide-linked Fvs (sdFv) fragments, for example, as produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, intrabodies, nanobodies, synthetic antibodies, and epitope-binding fragments of any of the above.

[0069] As used herein, the term “humanized mouse” (Hu-mouse) is a mouse developed to carry functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. Immunodeficient mice are often used as recipients for human cells or tissues, because they can relatively easily accept heterologous cells due to lack of host immunity.

[0070] HSCs possess the ability of multipotency (*i.e.*, one HSC can differentiate into all functional blood cells) and self-renewal (*i.e.*, HSCs can divide and give rise to an identical daughter cell, without differentiation). Through a series of lineage commitment steps, HSCs give rise to progeny that progressively lose self-renewal potential and successively become

more and more restricted in their differentiation capacity, generating multi-potential and lineage-committed progenitor cells, and ultimately mature functional circulating blood cells.

[0071] The ability of hematopoietic stem and progenitor cells (HSPCs) to self-renew and differentiate is fundamental for the formation and maintenance of life-long hematopoiesis and deregulation of these processes may lead to severe clinical consequences. HSPCs are also highly valuable for their ability to reconstitute the hematopoietic system when transplanted and this has enabled their use in the clinic to treat a variety of disorders including bone marrow failure, myeloproliferative disorders and other acquired or genetic disorders that affect blood cells.

[0072] As used herein, a “pluripotent cell” refers to a cell derived from an embryo produced by activation of a cell containing DNA of all female or male origin that can be maintained *in vitro* for prolonged, theoretically indefinite period of time in an undifferentiated state that can give rise to different differentiated tissue types, *i.e.*, ectoderm, mesoderm, and endoderm. “Embryonic stem cells” (ES cells) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo.

[0073] As used herein, an “autologous transplant” refers to a transplant that uses a subject’s own stem cells. These cells are collected in advance and returned at a later stage. Thus, an “allogeneic transplant” refers to a transplant where the donor and the recipient of the stem cells are different people. Exemplary allogeneic cells include, but are not limited to, syngeneic cells, MHC-matched cells, etc.

[0074] As used herein “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.

[0075] As used herein, a “lysosomal protein disorder” or “lysosomal protein disease” refers to any metabolic disorders that result from defects in lysosomal function. Also referred to as “lysosomal storage disorders”, such diseases/disorders are typically caused by lysosomal dysfunction usually as a consequence of deficiency of a single enzyme required for the metabolism of lipids, glycoproteins (sugar containing proteins) or so-called mucopolysaccharides. Exemplary lysosomal storage disorders include, but are not limited to, cystinosis, Salla disease, infantile sialic acid storage disorder, Cobalamin F-type disease, neuronal ceroid lipofuscinosis (both late infantile and juvenile forms), malignant infantile

osteopetrosis, mucopolipidosis IV, mucopolysaccharidosis type IIIC (Sanfilippo syndrome C), Niemann-Pick Type C, and Danon disease (Ruivo, *et al. Biochimica et Biophysica Acta* 1793 (2009) 636-649, incorporated herein by reference).

[0076] For example, Cystinosis is an autosomal metabolic disease that belongs to the family of the lysosomal storage disorders. Cystinosis has a devastating impact on the affected individuals, primarily children and young adults, even with cysteamine treatment. The prevalence of cystinosis is 1:100,000 to 1:200,000. The gene involved in cystinosis is the gene CTNS that encodes for the 7-transmembrane lysosomal cystine transporter, cystinosin. The most severe and the most frequent form of cystinosis is the infantile form, also called nephropathic cystinosis. Children develop a renal Fanconi syndrome at 6-8 months of age, characterized by severe fluid and electrolyte disturbance, growth retardation and rickets. Progressive loss of glomerular function leads to renal failure; according to NAPRTCS' (North American Pediatric Renal Trials and Collaborative Studies), 1.4% of children on dialysis (2011 Annual Dialysis Report) and 2.1% with kidney transplants (2010 Annual Transplant Report) have cystinosis. Cystinosis as a clinical entity is also a progressive dysfunction of multiple organs caused by the accumulation of cystine in the lysosomes of all the cells in the body; affected patients store 50-100 times the normal amounts of cystine in their cells.

[0077] Cystine storage leads to the formation of cystine crystals in all tissues. The main clinical complications in cystinosis include to diabetes, hypothyroidism, myopathy and central nervous system deterioration. Corneal cystine crystals appear from the first decade of life resulting in photophobia and visual impairment. Swallowing difficulties, directly correlated with muscle atrophy, is a major cause of death in cystinosis. In addition to cystine builds up, cellular dysfunctions such as abnormal vesicular trafficking, autophagy and TFEB (Transcription Factor EB) signaling have also been described as responsible for the pathogenesis of cystinosis.

[0078] The current treatment for cystinosis is the drug cysteamine (mercaptoethylamine), which reduces the intracellular cystine content. However, this therapy only delays disease progression and has no effect on renal Fanconi syndrome nor does it prevent end stage renal failure in affected patients. Cysteamine has also been shown to be inefficient to improve cellular dysfunctions in CTNS-deficient cells, proving that cellular defects in cystinosis are not only due to cystine accumulation but also due to the lack of the cystinosin itself that interacts directly with key cellular components.

[0079] In addition, cysteamine has to be taken every 6 hours including at night, and results in bad body odor as well as severe gastrointestinal side effects such as vomiting and diarrhea that render treatment compliance difficult. In 2013, a delayed-release formulation of cysteamine (PROCYSBI®) was FDA-approved, which requires dosing every 12 hours. While PROCYSBI® reduces the number of doses improving the patients' quality of life, the impact on the disease is similar than immediate release cysteamine and patients still experience gastric side effects. Moreover, the cost of this medication is very high, \$300,000-\$600,000 per year per patient.

[0080] The ocular pathology in cystinosis requires topical administration of cysteamine eye drops every hour, which causes irritation and burning so compliance is very challenging. The cost of eye drops is about \$50,000 per year per patient. Cysteamine and the supportive treatment for all the complications associated with cystinosis requires patients to take up to 60 pills per day; the kids often require placement of a gastric tube to be able to tolerate the medications and get essential caloric intake. Medical complications increase in severity and number with age resulting in new and ever-increasing symptoms and treatments. There are unending doctor appointments, G-tube feedings, frequent blood draws, growth hormones shots, bone pain, daily vomiting, eye pain and severe gastrointestinal side effects. As the disease progress, their bodies deteriorate. The most severe complications for adults are myopathy, pulmonary issues and progression of corneal cystinosis. Patients with renal failure require dialysis or transplantation, both of which have significant negative health effects and due to the severe shortage of donor organs, patients may wait three to six years for transplantation. Thus, the current standard of care does not prevent the progression of the disease and significantly impacts the quality of life for patients with cystinosis who still die in early adulthood.

[0081] Danon disease has many similarities to other lysosomal membrane protein diseases and is characterized as a disorder of autophagy that affects the degradation of many cellular components and thus does not result in the accumulation of a single substrate. Danon disease has been more recently described as an autophagic vacuolar myopathy. Danon disease is caused by mutations in the gene encoding lysosomal associated membrane protein 2 (LAMP-2), resulting in decreased expression of the LAMP-2 protein. Loss of LAMP-2 expression disrupts autophagic flux, impairing the ability of cells to respond to stress and remove damaged cellular components.

[0082] Thus, the present disclosure demonstrates that one-time hematopoietic stem and progenitor cell (HSPC) transplantation holds the potential to become a life-long curative therapy for a disease or disorder associated with a defective lysosomal transmembrane protein. The therapy may further prevent kidney transplantation and long-term complications associated with cystinosis including unexpectedly the clearance of the corneal cystine crystals. This should also allow patients to withdraw from oral cysteamine, cysteamine eye drops and any other medications used for treating symptoms associated with the disease. As such, the quality of life of the patients is greatly improved and the cost of treatment highly decreased.

[0083] Due to the multi-systemic nature of cystinosis and all the drugs necessary to compensate for the absence of the protein, cystinosin, in every tissues, a gene therapy approach was investigated. Gene therapy has the potential to become an important new approach for the third millennium to treat both rare and common severe diseases because its reach extends well beyond that of conventional drugs and offers the prospect of a curative stem cell-based therapy with limited risks as compared to allogeneic HSC transplantation. Hematopoietic stem and progenitor cells (HSPCs) are therefore ideal candidates for use in regenerative medicine and cell replacement therapies because of their ease of isolation, self-renewal capacity, and safety. Moreover, gene therapy can address unmet medical need such as in the case of cystinosis, especially this strategy overcomes the unavailability of matched HSC donor and makes the treatment potentially available to all patients.

[0084] Using a rodent model of cystinosis, *Ctns*^{-/-} mice, it has been shown that transplantation of HSCs expressing a functional *Ctns* gene resulted in abundant tissue integration of bone marrow-derived cells, significant decrease of cystine accumulation (up to 97% clearance), and long-term kidney preservation. Indeed, while non-treated *Ctns*^{-/-} mice progressed to end-stage renal failure, age-matched *Ctns*^{-/-} mice transplanted with wild-type HSCs maintained normal renal function after more than a year post-transplant. Few to no cystine crystals were observed in the kidneys of treated mice, in contrast to non-treated *Ctns*^{-/-} mice, in which abundant cystine crystals were consistently observed in the kidney. It has also recently been demonstrated that HSC transplantation rescues eye defects in the *Ctns*^{-/-} mice. Treated *Ctns*^{-/-} mice exhibited almost complete resolution of cystine crystals from the epithelial layer to the middle stroma (100% to 72% reduction, respectively), and normal corneal thickness and intraocular pressure. The impact of transplanted HSCs on the thyroid gland has also been studied. *Ctns*^{-/-} mice present with sustained TSH activation combined with thyrocyte hypertrophy, hyperplasia and vascular proliferation. In contrast, *Ctns*^{-/-} mice treated with

transplanted HSCs exhibited normalization of cystine and TSH values and normal histology. These studies are the first proof of concept that one single HSC transplantation could prevent the multi-organ degeneration associated with cystinosis

[0085] As such, the present disclosure evaluates the impact of HSPC transplantation in a mouse model for cystinosis (Ctns^{-/-} mice). Using a mouse model of cystinosis (Ctns^{-/-} mice), the present disclosure demonstrates that transplantation of wildtype (WT) murine hematopoietic stem cells (mHSCs) led to abundant tissue integration of bone marrow-derived cells, significant decrease of tissue cystine accumulation (up to 97% reduction) and long-term kidney, eye and thyroid preservation. Given the risks of mortality and morbidity associated with allogeneic HSC transplantation, such as graft-versus-host diseases (GVHD), an autologous transplantation protocol of HSCs was developed for *ex vivo* modification. Using a self-inactivated-lentiviral vector (SIN-LV) to introduce a functional version of the CTNS cDNA, pCCL-CTNS (backbone pCCL-EFS-X-WPRE), efficacy in Ctns^{-/-} mice has been shown.

[0086] *In vitro* studies using human CD34⁺ HSPCs isolated from peripheral blood of healthy donors and cystinosis patients have now completed, and the serial transplantation in the Ctns^{-/-} mice has been significantly advanced. Thus, the data provided herein demonstrates efficacy of transplantation of CD34⁺ HSCs from G-CSF mobilized peripheral blood stem cells (PBSC) of patients with cystinosis, modified by *ex vivo* transduction using the pCCL-CTNS LV.

[0087] Cystinosis and Danon disease both arise from loss of function mutations in transmembrane lysosomal proteins, Cystinosin and LAMP-2, respectively. In fact, Cystinosin is localized to LAMP-2 positive vesicles that are transferred during cross-correction. Thus, the present disclosure also demonstrates that bone marrow was harvested from patients with Danon disease and sorted for CD34⁺ hematopoietic stem cells (HPSCs). After harvest, patient HPSCs are genetically-modified using viral transduction vectors including, but not limited to, lentiviruses and other retroviruses carrying any normal variant of the LAMP-2 gene and/or any of the LAMP-2 splice isoforms (*e.g.*, LAMP-2A, LAMP-2B, LAMP-2C), referred to hereafter collectively as “wild-type LAMP-2” or “WT LAMP-2”, is inserted into the genome of the harvested HPSCs. After infection, the viral vector inserts the wild-type LAMP-2 transgene into the host cell genome at specific sites that limit genome disruption. This insertion allows the wild-type LAMP-2 transgene to then be stably expressed by the host cell.

Following translation, the wild-type LAMP-2 protein is trafficked to the lysosomal membrane where it embeds and assumes its normal intracellular position. Introduction of the wild-type LAMP-2 protein into the lysosomal membrane restores autophagic flux, allowing the cell to function normally.

[0088] After the wild-type LAMP-2 gene has been introduced, the HPSCs are transplanted back into the patient from which they were harvested. These cells then re-engraft in the patient's bone marrow and begin to produce progenitor cells. Some of these progenitor cells differentiate into monocytes carrying the wild-type LAMP-2 gene. Monocytes with the wild-type LAMP-2 gene enter the circulation and subsequently invade the peripheral tissues where they transform into tissue resident macrophages. These macrophages, through a variety of mechanisms including, but not limited to, the formation of tunneling nanotubes, vesicular release, and direct cell-cell adhesion they transfer their lysosomes, which carry membrane-bound wild-type LAMP-2 protein, to diseased peripheral cells. Wild-type LAMP-2 protein may also be transferred between macrophages and diseased peripheral cells in additional forms including, but not limited to, as free protein or bound to other proteins, membranes or organelles. The transfer of wild-type LAMP-2 containing lysosomes or wild-type LAMP-2 in other forms restores normal autophagic flux in the diseased cells resulting in partial or complete amelioration of the Danon phenotype.

[0089] Accordingly, in one aspect, the invention provides a method of treating a lysosomal transmembrane protein disease or disorder in a subject. The method includes introducing *ex vivo* a functional human transmembrane protein corresponding to the disorder to be treated into HSPCs of the subject, and thereafter transplanting the HSPCs into the subject, thereby treating the lysosomal transmembrane protein disease or disorder. Thus, for example, when the disease or disorder to be treated is cystinosis, the functional human transmembrane protein to be introduced is CTNS. In various embodiments, the vector is a self-inactivating (SIN)-lentivirus vector, such as, for example, pCCL-CTNS (in the case of CTNS). Likewise, when the disease or disorder to be treated is Danon disease, the functional human transmembrane protein to be introduced is LAMP-2. In various embodiments, the step of introducing may include contacting a vector comprising a polynucleotide encoding the functional protein (*e.g.*, CTNS or LAMP-2) and a functional promoter (*e.g.*, an ubiquitous or endogenous promoter of the functionally protein) with the HSPCs and allowing expression of the functional protein. As such, the present disclosure provides a method for autologous transplantation of *ex vivo* gene-

modified HSPCs to introduce a functional protein associated with a specific lysosomal transmembrane protein disease or disorder.

[0090] In various embodiments, the lysosomal transmembrane protein diseases or disorders include, but are not limited to, cystinosis, Salla disease, infantile sialic acid storage disorder, Cobalamin F-type disease, neuronal ceroid lipofuscinosis (both late infantile and juvenile forms), malignant infantile osteopetrosis, mucopolidosis IV, mucopolysaccharidosis type IIIC (Sanfilippo syndrome C), Niemann-Pick Type C, and Danon disease. Without being bound by theory, in cystinosis and free sialic acid storage diseases, transporters for cystine and acidic monosaccharides, respectively, are blocked or retarded. A putative cobalamin transporter and a hybrid transporter/transferase of acetyl groups are defective in cobalamin F type disease and mucopolysaccharidosis type IIIC, respectively. In neurodegenerative forms of osteopetrosis, mutations of a proton/chloride exchanger impair the charge balance required for sustained proton pumping by the V-type ATPase, thus resulting in bone-resorption lacuna neutralization. However, the mechanism leading to lysosomal storage and neurodegeneration remains unclear. Mucopolidosis type IV is caused by mutations of a lysosomal cation channel named TRPML1; its gating properties are still poorly understood and the ion species linking this channel to lipid storage and membrane traffic defects is debated. Finally, the autophagy defect of Danon disease apparently arises from a role of LAMP2 in lysosome/autophagosome fusion, possibly secondary to a role in dynein-based centripetal motility. (Ruivo, *et al. Biochimica et Biophysica Acta* 1793 (2009) 636-649, incorporated herein by reference).

[0091] Table 1 sets forth the exemplary lysosomal transmembrane protein diseases or disorders to be treated with *ex vivo* introduction of corresponding functional human transmembrane proteins.

Table 1

Human disease/disorder	Causative gene, locus	Protein name (aliases)	Protein size, # of transmembrane helices (TM)
Cystinosis	<i>CTNS</i> , 17p13	Cystinosin	367 aa; 7 TM
Salla disease, infantile sialic acid storage disorder	<i>SLC17A5</i> , 6q14-q15	Sialin	495 aa; 12 TM
Cobalamin F-type disease	<i>LMBRD1</i> , 6q13	LMBD1 (probable lysosomal cobalamin transporter)	540 aa; 9 TM

Neuronal ceroid lipofuscinosis, late infantile variant	<i>MFSD8</i> , 4q28.1-q28.2	CLN7 (major facilitator superfamily domain-containing protein 8)	518 aa; 12 TM
Neuronal ceroid lipofuscinosis, juvenile form	<i>CLN3</i> , 16p12.1	CLN3 (Battenin)	438 aa; 6 TM
Malignant infantile osteopetrosis	<i>CLCN7</i> , 16p13 <i>OSTM1</i> , 6q21	ClC-7 OSTM1	805 aa; 18 TM 338 aa; 1 TM
Mucopolidosis IV	<i>MCOLN1</i> , 19p13.3-p13.2	TRPML1 (mucolipin-1, MLN1)	580 aa; 6 TM
Mucopolysaccharidosis type IIIC (Sanfilippo syndrome C)	<i>HGSNAT</i> , 8p11.1	HGSNAT (TMEM76)	663 aa; 11 TM
Niemann-Pick Type C	<i>NPC1</i> , 18q11-q12	NPC1	1278 aa; 11 TM
Danon disease	<i>LAMP2</i> , Xq24	LAMP2 (LAMPB, LGP110)	410 aa; 1 TM

[0092] Vectors derived from lentiviruses have supplanted γ -retroviral vector for gene therapy due to their superior gene transfer efficiency and better biosafety profile. Indeed, all cases of leukemogenic complications observed to date in clinical trials or animal models involved the use of retroviral vectors with LTR containing strong enhancer/promoters that can trigger distant enhancer activation. In contrast, the third-generation of lentivirus vectors, SIN-LV, with the deletions in their LTR, contains only one internal enhancer/promoter, which reduces the incidence of interactions with nearby cellular genes, and thus, decreases the risk of oncogenic integration. SIN-LV are also designed to prevent the possibility of developing replication competent lentivirus (RCL) during production of viral supernatants with three packaging plasmids necessary for production. Lentivirus vectors efficiently transduce HSPCs and do not alter their repopulation properties, which make this type of vector an attractive vehicle for stem cell gene therapy.

[0093] Clinical trials using SIN-LV to gene-correct human HSPCs are being undertaken in the U.S. and Europe for several conditions including HIV-1, β -thalassemia, immune deficiencies, metabolic diseases and cancers. For immune deficiency disorders, 35 patients have been transplanted with SIN-LV-modified HSPCs so far. A clinical trial in patients with Adrenoleukodystrophy (ALD) has achieved stable gene correction in ~20% of hematopoietic cells in two patients. Cerebral demyelination was arrested without further progression over three years of follow-up, which represents a clinical outcome comparable to that observed after

allogeneic transplantation; there was no evidence of clonal dominance. Recently, a clinical trial for Wiskott-Aldrich syndrome was reported in three patients 32 months post-transplantation. Stable and long-term engraftment of the gene-modified HSPCs (25-50%) resulted in improved platelet counts, protection from bleeding and infections, and resolution of eczema. Another clinical success was recently reported in three pre-symptomatic patients with Metachromatic Leukodystrophy. Transduced cell-derived blood cell engraftment achieved 45 to 80%, and up to 24 months later, protein activity was reconstituted to above normal values in cerebrospinal fluid associated with a clear therapeutic benefit.

[0094] The recent gene therapy successes using AAV vectors in the MCK mice not only prevented heart failure when given to presymptomatic animals, but also reversed the cardiomyopathy when given after the onset. While encouraging, this approach presents potential safety and logistic concerns: i) localized delivery by direct viral injection to affected sites poses certain challenges in accessing sites such as heart and brain and leads only to tissue-specific rescue, ii) systemic AAV delivery remains difficult in humans due to the high levels of vector necessary, leading to vector synthesis and safety concerns. In contrast, HSPC gene therapy approach has the key advantages: i) it treats all the complications by a single infusion of stem cells, ii) gene-correction occurs *ex vivo* in a controlled environment allowing cell characterization prior to transplantation, iii) gene-corrected HSPCs reside in the bone marrow niche after transplantation where they self-renew and become a reservoir of healthy cells for the lifespan of the patients, iv) it avoids immune reaction as compared to allogeneic transplantation. Thus, autologous HSPC gene therapy could provide a cure for lysosomal transmembrane protein diseases or disorders.

[0095] Amino acid and nucleic acid sequences for the human proteins set forth in Table 1 are known in the art. See, for example, GenBank Accession No.: Y15924.1, human CTNS gene, exon 3, flanking intronic regions and joined CDS, which provides the amino acid sequence (SEQ ID NO: 1):

```
MIRNWLTI FILFPLKLVEKCESSVSLTVPPVVKLENGSSTNVSLTLRPPLNATLVITFEITFRSKNITILELPDEV
VVP PGVTNSSFQVTSQNVGQLTVYLHGNHSNQTGPRI RFLVIRSSAISIIINQVIGWIYFVAWSISFY PQVIMNWR
KSVIGLSFDFVALNLTGFVAYSVFNIGLLWVPYIKEQFLLKYPNGVNPVNSNDVFFSLHAVVLTLLIIIVQCCLYER
GGQRVSWPAIGFLVLAWLFAFVTMIVA AVGVITWLQFLFCFSYIKLAVTLVKYFPQAYMNFYKSTEGWSIGNVLL
DFTGGSFSL LQMFLQSYNNDQWTLIFGDPTKFGLGVFSIVFDVVFQHFCLYRKRP GYDQLN
```

GenBank Accession No.: AJ222967.1, human CTNS mRNA, which provides the nucleic acid sequence (SEQ ID NO: 2):

```

cgctctctccc aaagtctagc cgggcagggg aacgcggtgc attcctgacc ggcacctggc gaggctcatg
cgtcccgtga gggcggttcc tcgagcctgg gggcgctcag attgctttgg agacgctgag agaacccttg
cgagagcgcc ggttgacgtg cggagtgcgg ggctccgggg gactgagcag cacgagaccc catcctcccc
tccggggtttt cacactgggc gaagggagga ctcttgagct ctgcctcttc cagtaacatt gaggattact
gtgtttttgtg agagctcgct aggcgcctta agcaacagag ttctgagaaa tcgagaaaca tgataaggaa
ttggctgact atttttatcc tttttccctt gaagctcgta gagaaatgtg agtcaagcgt cagcctcact
gttcctcctg tcgtaaagct ggagaacggc agctcgacca acgtcagcct caccctgcgg ccaccattaa
atgcaaccct ggtgatcact tttgaaatca catttcgttc caaaaatatt actatccttg agctccccga
tgaagtgtg gtgcctcctg gagtgacaaa ctctcttttt caagtgcacat ctcaaaatgt tggacaactt
actgtttatc tacatggaaa tcaactccaat cagaccggcc cgaggatacg ctttcttggtg atccgcagca
gcgccattag catcataaac caggtgattg gctggatcta ctttggtggc tgggtccatct ccttctaccc
tcaggtgatc atgaattgga ggcggaaaag tgtcattggg ctgagcttcg acttcgtggc tctgaacctg
acaggcttcg tggcctacag tgtattcaac atcggcctcc tctgggtgcc ctacatcaag gagcagtttc
tctcaataa cccaacgga gtgaaccccg tgaacagcaa cgacgtcttc ttcagcctgc acgcggtgtg
cctcacgctg atcatcatcg tgcagtgcgt cctgtatgag cgcggtggcc agcgcgtgtc ctggcctgcc
atcggcttc tgggtgctgc gtggctcttc gcatttgtca ccatgatcgt ggctgcagtg ggagtgatca
cgtggctgca gtttctcttc tgcttctcct acatcaagct cgcagtcacg ctggtcaagt attttccaca
ggcctacatg aacttttact acaaaagcac tgagggctgg agcattggca acgtgctcct ggacttcacc
gggggcagct tcagcctcct gcagatgttc ctccagtcct acaacaacga ccagtggacg ctgatcttcg
gagacccaac caagtttgga ctcggggtct tctccatcgt cttecgacgtc gtcttcttca tccagcactt
ctgtttgtac agaaagagac cggggtatga ccagctgaac tagcaccag ggacccagtg taccagcct
ctggcctcgt gccctgctgg ggaaggcctc acccagcgaa ggccggagaa gcggttgggc cctggcacac
agggctggct cagtgtgcgg acagaggaga ccactctgct cctggggcca gaggccattc aatagcctgc
cttcgtccgg gccctcctg ggccctcccc gccaggcacg tggcacctgc gccttgacac cgccatctct
tttctttaag gcttcaggca gcgcgcacag gctctggcag ccgtctcagg caggactggg caccaagctt
gcagccgaag gccttgcccc aaactaccag cgtttctgca agcagcttga agggctgacc ttgcagccgg
gtgagccaag ggcactttgc tgccaccgct gcattcccag agatcaagca gcccggtgcc gtggccagtg
aactcagagg tgctggtgga cgggctagga ctttgggggt aggccatggg gctctttctc tgaaggccac
tttcctgacg tactctctgt acataactca gcgtccgtga ctgcagtaac agccagccct acccagagta
tttctgagcc atgaggggcc caccagattg gttctgaatt ggattcatgc ccagcgcatt agcatagtaa
ctcctttcag attttttgga gggacgtttg gaagtggctt actctcttct gccctctctc ctacctccac
cttctcagat gagccccatc tgagcacatc cagctgctcc ttaccagca tctggagtac aggacatagc
tctctcctgc taccagtctg tgcccttagag gtcgttaggc ctgccaaacg gcgaccagct cccctggagc
gagggcaggc cccttccctc tctttcccca gacacctact tgagactcac caatttctgg cctgttcagg
agcctcagat aagtatttgt acttgagacc acctcacaca atctgtatgg gcccaaccct gatctcaaac
ctccttccct ctgccccaaag ctgtccttcc tatggcagga ggggtggggg tcccaggacg tgcctcatat
atgacttgag cttgtcagtc cactgagttt cttctacga gatcaacgcg aggggcctgt atcttgaatt
aaagcctact cgcttccttt c

```

GenBank Accession No.: CAB62540.1, human sialin, which provides the amino acid sequence (SEQ ID NO: 3):

```

MRSPVRDLAR NDGEESTDRT PLLPGAPRAE AAPVCCSARY NLAILAFFGF FIVYALRVNL SVALVDMVDS
NTTLEDNRTS KACPEHSAPI KVHHNQTGKK YQWDAETQGW ILGSFFYGYY ITQIPGGYVA SKIGGKMLLG
FGILGTAVLT LFTPIAADLG VGPLIVLRAL EGLGEGVTFP AMHAMWSSWA PPLERSKLLS ISYAGAQLGT
VISLPLSGII CYYMNWTYVF YFFGTIGIFW FLLWIWLVSD TPQKHKRISH YEKEYILSSL RNQLSSQKSV
PWVPILKSLP LWAIIVVAHFS YNWTFYTLT LLPTYMKEIL RFNVQENGFL SSLPYLGSWL CMILSGQAAD
NLRKWNFST LCVRRIFSLI GMIGPAVFLV AAGFIGDYS LAVAFLTIST TLGGFCSSGF SINHLDIAPS
YAGILLGITN TFATIPGMVG PVIKSLTPD NTVGEWQTVF YIAAAINVFG AIFFTLFAKG EVQNWALNDH
HGHRH

```

GenBank Accession No.: AJ387747.1, human sialin mRNA, which provides the nucleic acid sequence (SEQ ID NO: 4):

```

cggctacttt gcgccaatcc tacgagaact ccagaaactc cgcttcccta gtccaacca agccagagtt
gccacacct aagatggcgg cggggggcgg agtcggcgcg gccgcctctg ggcgggaccg cggggactag
acgtggccgc ggggcggtgt catcgcccc gccccgccc gtccagccag ctcgccccgg gggcttcggg
ctgtcgggcc ggcgctccct tctctgccag gtggcgagta cacctgctca cgtaggcgtc atgaggtctc
cggttcgaga cctggccccg aacgatggcg aggagagcac ggaccgcacg cctcttctac cgggcgcccc
acgggcccga gccgctccag tgtgctgctc tgctcgttac aacttagcaa ttttggcctt ttttggtttc

```

```

ttcatttgtgt atgcattacg tgtgaatctg agtggttgcgt tagtggatat ggtagattca aatacaactt
tagaagataa tagaacttcc aaggcgtgtc cagagcattc tgctcccata aaagttcatc ataatcaaac
gggtaagaag taccaatggg atgcagaaac tcaaggatgg attctcgggt ccttttttta tggctacatc
atcacacaga ttcttgagg atagtgtgcc agcaaaatag gggggaaaat gctgctagga tttgggatcc
ttggcactgc tgtcctcacc ctgttcactc ccattgctgc agatttagga gttggaccac tcattgtact
cagagcacta gaaggactag gagagggtgt tacatttcca gccatgcatg ccatgtgggtc ttcttgggct
ccccctcttg aaagaagcaa acttcttagc atttcatatg caggagcaca gcttgggaca gtaatttctc
ttcctctttc tggaataatt tgctactata tgaattggac ttatgtcttc tacttttttg gtactattgg
aatatttttg tttcttttgt ggatctgggt agttagtgc acaccacaaa aacacaagag aatttcccat
tatgaaaagg aatacattct ttcattatta agaaatcagc tttcttcaca gaagtcagt ccgtgggtac
ccattttaaa atccctgcc ctttgggcta tcgtagtgtc acacttttct tacaactgga ctttttatac
tttattgaca ttattgccta cttatatgaa ggagatccta aggttcaatg ttcaagagaa tgggttttta
tcttcattgc cttatttagg ctcttgggtt tgtatgatcc tgtctgggtc agctgctgac aatttaaggg
caaatggaa tttttcaact ttatgtgttc gcagaatttt tagccttata ggaatgattg gacctgcagt
attcctggta gctgctggct tcattggctg tgattattct ttggccgttg ctttcctaac tatatcaaca
acactgggag gcttttgctc ttctggattt agcatcaacc atctggatat tgctccttcg tatgctggta
tcctcctggg catcacaaat acatttgcca ctattccagg aatgggtggg cccgtcattg ctaaaagtct
gacccctgat aacactggtg gagaatggca aaccgtgttc tatattgctg ctgctattaa tgtttttggg
gccattttct ttacactatt cgccaaagg gaagtacaaa actgggctct caatgatcac catggacaca
gacactgaag gaaccaataa ataatcctgc ctctattaat gtatttttat ttatcatgta acctcaaagt
gccttctgta ttgtgtaagc attctatgtc tttttttaat tgtacttgta ttagattttt aaggcctata
atcatgaaat atcactagtt gccagaataa taaaatgaac tgtgtttaat tatgaataat atgtaagcta
ggacttctac tttagggtca catacctgcc tgctagtcgg gcaacatgaa gtaggacagt tctgttgatt
ttttagggcc atactaaagg gaatgagctg aaacagacct cctgatacct ttgcttaatt aaactagatg
ataattctca ggtactgata aacacctgtt gttgttctact ttcctcataa aaattgtcag ctctctctga
cacttagacc tcaaacttta gcatctctgt ggagctgcca tccactgtat aatttcgcct ggcaactgga
ctgaggggag tgtgcccagg cagctgccaa gcactccctc cctggcttca gggtcagagt gccagcgtt
tatcagaggc agcatccaag ccagagacca gtgtcgactc ttcggctggg gcctttcctc tgaggggcta
tcaatgtgta gataaagccc tgagtaggca agagcagtga gatccactgc tatgggtctg atacatcctc
aaactttccc ttcccagcac agaggaatat tggctggcat gcaacctgca aaagaaaaat gc

```

GenBank Accession No.: CCP79466.1, human LMBD1, which provides the amino acid sequence (SEQ ID NO: 5):

```

GAASAELVIGWCIFGPLLLAIFAFWCWIYVRKYQSQRESEVVSTITAI FSLAIALITSALLPVDIFLVSYMKNQNGT
FKDWANANVSRQIEDTVLYGYYTLYSVILFCVFFWIPFVYFYEEKDDDDTSKCTQIKTAFKYTLGFAVICALLLL
VGAFVPLNVPNNKNSTEWKVKFLFEELGSSHGLAALSFSISSLT LIGMLAAITYTAYGMSALPLNLIKTRSAAY
ERLENTEDIEEVEQHIQTIKSKSKDGRPLPARDKRALKQFEERLRTLKRERHLEYIENSWWTKFCGALRPLKIIW
GIFFILVALLFIISLFLSNLDKALHSAGIDSGFII FGANLSNPLNMLLPVLQTVFPLDYILITIIIMYFI FTSMAG
IRNIGIWFFWRLYKIRRGTRTPQALLFLCMILLLIVLHTSYMIYSLAPQYVMYGSQNYLIESNITYDDHKNNSAF
PVPKRCADAPEDQCTVTRTYLFLHKFWFFSAAYYFGNWAFLVVFLIGLIVSCCKGKKSVEGVDEDDSDISDDEP
SVYSV

```

GenBank Accession No.: HAAF01007642.1, human LMBD1 transcribed RNA, which provides the nucleic acid sequence (SEQ ID NO: 6):

```

ggcgcggtt cgcgcgagct ggtgatcggc tgggtgcatat ttggccctt actactggct atttttgcat
tctgttggat atatgttcgt aaataccaaa gtcagcggga aagtgaagtt gtctccacca taacggcaat
tttttctctg gcgattgcac ttatcacatc agcacttctt ccagtggata tatttttggg ttcttacatg
aaaaatcaaa atggtacatt taaggactgg gccaatgcta atgtcagcag acagatcgag gacactgtgt
tatatgggta ctacacctta tattctgtta tattattctg tgtgtttttc tggatccctt ttgtctactt
ctactatgaa gaaaaggatg atgatgatac tagtaaatgt actcaaatta aaactgcatt caagtatact
ttgggatttg ctgtaatttg tgcacttctt ctttttagttg gagcttttgt tcctctaaat gttcctaata
acaaaaattc tacagagtgg gaaaaagtga agttcctgtt tgaagaactt ggaagtagtc atggtttagc
tgcattgtca ttttctatta gttctctgac cttgattgga atgttggcag ctataactta cacagcctat
ggcatgtctg cattaccttt aaatctaata aaaggcacta gaagcgctgc ttacgaacgt ttagaaaaca
ctgaagacat tgaagaagtg gagcaacaca ttcaaacgat taaatcaaaa agcaaagatg gtcggccttt
gccagcaagg gataaacgcg ctttaaaaca atttgaagaa aggttaagaa cacttaggaa aagagagagg
cacttagaat acattgaaaa cagctgggtg acaaaatttt gtgggtgctct gcgtcccctg aagatcattt
ggggaatatt tttcatctta gttgcattgc tgtttataat ttctctcttc ctgtcaaatt tggataaagc

```

```

ccttcattca gctggaatag attctgggtt tataatTTTT ggagctaact tgagtaatcc actgaatatg
cttttgcttg tactacaaac agtgtttcc cttgattata ttcttataac aattattatt atgtacttta
tttttacttc aatggcggga attcgaaata tcggcatatg gttcttttgg gttagactat ataaaattag
aagaggtaga accaggcccc aggcctctct atttctttgc atgatacttc tgcttattgt ccttcacact
agctacatga tttatagtct tgctcccaa tatgtcatgt atggaagcca aaattactta atagagagca
atataactta tgatgaccat aaaaacaatt cagccttccc tgtgccaaag agatgtgatg ctgatgcccc
tgaagaccaa tgtactgtta cgcggacata cctgttccct cacaagttct gggtcttttag tgctgcatac
tattttggta actgggcttt tcttgtggta ttcttgattg gattaattgt atcctgttgt aaagggaga
aatcagtcac tgaaggagta gatgaagatg attcagacat aagtgatgat gagccctctg tctattctgt
ttgagagcct ctgtcttagg ggttttataa tgctgactga atgtctatta tgcatttttt aaagtgttaa
actaacatta ggatgaactg actagcttca tcaaaaatgg gagcatggct attaaaaaaa ctatatTTTT
tatgttatct gaagtaacat tattgtatca tagattaaca tttaaaattg ctgtaataat tctatgtaaa
tataaaacta tggactttgt gagggaatgt ttgtggaaat cttttttctc tagtgataaa tagtgttgaa
ttgattaaaa gtcttccaga attaatatc cctcttgtca cttcttaaaa acataataaa tcacttctac
ctgtgcaaaa aaaaaaaaa

```

GenBank Accession No.: AAH295036.1, human CLN7, which provides the amino acid sequence (SEQ ID NO: 7):

```

MAGLRNESEQ EPLLGDTPGS REWDILETEE HYKSRWRSIR ILYLTMFLSS VGFSVVMMSI WPYLQKIDPT
ADTSFLGWVI ASYSLGQMV A SPIFGLWSNY RPRKEPLIVS ILISVAANCL YAYLHIPASH NKYYMLVARG
LLGIGAGNVA VVRSYTAGAT SLQERTSSMA NISMCQALGF ILGPVFQTCF TFLGEKGVTV DVIKLOINMY
TTPVLLSAFL GILNIILILA ILREHRVDDS GRQCKSINFE EASTDEAQVP QGNIDQVAVV AINVLFVFTL
FIFALFETII TPLTMDMYAW TQEQAVLYNG IILAALGVEA VVIFLGVKLL SKKIGERAIL LGGLIVVWVG
FFILLPWGNQ FPKIQWEDLH NNSIPNTTFG EIIIGLWKSP MEDDNERPTG CSIEQAWCLY TPVIHLAQFL
TSAVLIGLGY PVCNLMSYTL YSKILGPKPQ GVYMGWLTAS GSGARILGPM FISQVYAHWG PRWAFSLVCG
IIVLTITLLG VVYKRLIALS VRYGRIQE

```

GenBank Accession No.: BC029503.1, human CLN7 mRNA, which provides the nucleic acid sequence (SEQ ID NO: 8):

```

aggttacaag cagcagatcc caccttcagt cctggctctg acaagccctc cagcttcacg ccacccggga
tgaggagaaag caggtgtcgc gagagttggg cgcaagacgc cttgtaggga gtgtaactat ggccggcctg
cggaacgaaa gtgaacagga gccgctctta ggcgacacac ctggaagcag agaatgggac attttagaga
ctgaagagca ttataagagc cgatggagat ctattaggat ttataatctt actatgtttc tcagcagtgt
agggttttct gtagtgatga tgtccatatt gccatatctc caaaagattg atccgacagc tgatacaagt
tttttgggct gggttattgc ttcatatagt cttggccaaa tggtagcttc acctatattt ggtttatggg
ctaattatag accaagaaaa gagcctctta ttgtctccat cttgatttcc gtggcagcca actgcctcta
tgcatatctc cacatcccag cttctcataa taaatactac atgctgggtg ctctgtggatt gttgggaatt
ggagcaggaa atgtagcagt tggtagatca tatactgctg gtgctacttc ccttcaggaa agaacaagt
ccatggcaaa cataagcatg tgtcaagcat taggttttat tctagggtcca gttttttcaga cttgttttac
attccttgga gaaaaagggt tgacatggga tgtgattaaa ctgcagataa acatgtatac aacaccagt
ttacttagcg ccttcctggg aatttttaaatt attattctga tccttgccat actaagagaa catcgtgtgg
atgactcagg aagacagtgt aaaagtatta attttgaaga agcaagtaca gatgaagctc aggttcccca
aggaaatatt gaccagggtg ctgttgtggc catcaatgtt ctgttttttg tgactctatt tatctttgcc
ctttttgaaa ccatcattac tccattaaca atggatatgt atgcctggac tcaagaacaa gctgtgttat
ataatggcat aatacttgct gctcttgggg ttgaagccgt tgttattttc ttaggagtta agttgctttc
caaaaagatt ggcgagcgtg ctattctact gggaggactc atcgttgtat gggttggctt ctttatcttg
ttaccttggg gaaatcaatt tcccaaaata cagtgggaag atttgcacaa taattcaatc cctaatacca
catttgggga aattattatt ggtcttttga agtctccaat ggaagatgac aatgaaagac caactgggtg
ctcgattgaa caagcctggg gcctctacac cccggtgatt catctggccc agttccttac atcagctgtg
ctaataggat taggctatcc agtctgcaat cttatgtcct atactctata ttcaaaaatt ctaggaccaa
aacctcaggg tgtatacatg ggctgggttaa cagcatctgg aagtggagcc cggattcttg ggcctatgtt
catcagccaa gtgtatgctc actggggacc acgatgggca ttcagcctgg tgtgtggaat aatagtgtc
accatcacc ccttgggagt ggtttacaaa agactcattg ctctttctgt aagatatggg aggattcagg
aataaactag ctaagactgt gatggaaact acttgctgtg tggcacttcc tggctctaaag ctctgctaga
caattgcggg gagccagtct ccaagaatca gactacagat attgcagatt ttgaagaaca agaacatatg
ttgaataaca gagagaattc tacatgtcat tgtgaatagt aggttatata aaaacatact agatgataat
ttcaaaaaaa aaaaaaaaa

```

GenBank Accession No.: AAB51075.1, human CLN3, which provides the amino acid sequence (SEQ ID NO: 9):

MGGCAGSRRRFS DSEGEETVPEPRLPLLDHQGAHWKNAVGFWLLGLCNNFSYVVMLSAAHDILSHKRTSGNQSHVD
PGPTPIPHNSSSRFDCNSVSTA AAVLLADILPTLVIKLLAPLGLHLLPYSPRVLVSGICAAGSFVLVAFSHSVGTSL
CGVVFASISSGLGEVTFLSLTAFYPRAVISWWSSGTGGAGLLGALS YLGLTQAGLSPQQTLLSMLGIPALLLAS YF
LL LTSPEAQDPGGEEEAESAARQPLIRTEAPESKPGSSSSLSLRERWTVFKGLLWYIVPLVVVYFAEYFINQGLFE
LLFFWNTSLSHAQQYRWYQMLYQAGVFASRSSLRCCRIRFTWALALLQCLNLVFL LADVWFGFLPSIYLVFLIILY
EGLLGGAAYVNTFHNIALET SDEHREFAMAATCISDTLGISLSGLLALPLHDFLCQLS

GenBank Accession No.: U32680.1, human CLN3 mRNA complete cds, which provides the nucleic acid sequence (SEQ ID NO: 10):

cccctagaca agccggagct gggaccggca atcgggcggt gatccttgct acctgtcgca gaccctcatc
cctcccgtgg gagccccctt tggacactct atgacctgga accctcgggg gacctgaact tgatgcgatg
ggaggctgtg caggctcgcg gcggcgcttt tcggattccg agggggagga gaccgtcccg gagccccggc
tccctctgtt ggaccatcag ggcgcgcatt ggaagaacgc ggtgggcttc tggctgctgg gcctttgcaa
caacttctct tatgtggtga tgctgagtgc cgccacgac atccttagcc acaagaggac atcgggaaac
cagagccatg tggaccagc cccaacgccc atccccaca acagctcatc acgatttgac tgcaactctg
tctctacggc tgctgtgctc ctggcggaca tcctccccac actcgtcatc aaattgttgg ctctcttgg
ccttcacctg ctgccctaca gccccgggt tctcgtcagt gggatttgtg ctgctggaag cttcgtcctg
gttgcccttt ctcatctctg ggggaccagc ctgtgtggtg tggctctcgc tagcatctca tcaggccttg
gggaggtcac cttcctctcc ctactgcct tctaccccag ggccgtgatc tcctggtggt cctcagggac
tgggggagct gggctgctgg gggccctgtc ctacctgggc ctcacccagg ccggcctctc ccctcagcag
accctgctgt ccatgctggg tatccctgcc ctgctgctgg ccagctatct cttgttgctc acatctcctg
aggcccagga ccctggaggg gaagaagaag cagagagcgc agcccggcag cccctcataa gaaccgaggc
cccggagtgc aagccaggct ccagctccag cctctccctt cgggaaaggg ggacagtatt caagggtctg
ctgtggtaca ttgttccctt ggtcgtagtt tactttgccc agtatttcat taaccaggga ctttttgaac
tcctcttttt ctggaacact tccttgagtc acgctcagca ataccgctgg taccagatgc tgtaccaggc
tggcgtcttt gcctcccgtc cttctctccg ctgctgtcgc atccgtttca cctgggcccct ggccctgctg
cagtgcctca acctggtgtt cctgctggca gacgtgtggt tcggctttct gccaaagcat tacctcgtct
tcctgatcat tctgtatgag gggctcctgg gaggcgcagc ctacgtgaac acctccaca acatcgccct
ggagaccagt gatgagcacc gggagtgttg aatggcggcc acctgcatct ctgacacact ggggatctcc
ctgtcggggc tcctggcttt gcctctgcat gacttcctct gccagctctc ctgatactcg ggatcctcag
gacgcaggtc acattcacct gtgggcagag ggacaggcca gacacccagg cccaccccag agaccctcca
tgaactgtgc tcccagcctt cccggcaggt ctgggagtag ggaagggtg aagccttgtt tccttgccag
ggggccagcc attgtctccc acttggggag tttcttctct gcatcatgcc ttctgaataa atgccgattt
tgtccatgg

GenBank Accession No.: AAF34711.1, human CLCN7, which provides the amino acid sequence (SEQ ID NO: 11):

MANVSKKVSWSGRDRDDEEAAPLLRRTARPGGGTPLLNGAGPGAARQSPRSALFRVGHMSSVELDDELDPDMDPP
HPFPKEIPHNEKLLSLKYESLDYDNSENQLFLEEERRINHTAFRTVEIKRWVICALIGILTGLVACFIDIVVENLA
GLKYRVIKGNIDKFTEKGLSFSLLLWATLNAAFVLVGSVIVAFIEPVAAGSGIPQIKCFLNGVKIPHVVRLKTLV
IKVSGVILSVVGGGLAVGKEGPMIHSGSVIAAGISQGRSTSLKRDFKIFEYFRDTEKRDFVSAGAAAGVSAAFGAP
VGGVLFSL EEGASFVNQFLTWRIFFASMI STFTLN FVLSIYHGNNMWDLSSPGLINFRFDSEKMAYTIHEIPVFIA
MGVVGGLVGA VFNALNYWLTMFRI RYIHRPCLQVIEAVLVA AVTATVAFVLIYSSRDCQPLQGGSMSYPLQLFCAD
GEYNSMAAAFFNTPEKSVVSLFHDPPGSYNPLTLGLFTLVYFFLACW TYGLTVSAGVFIPSL LIGAAWGR LFGISL
SYLTGAAIWADPGKYALMGAAAQLGGIVRMTLSLTVIMMEATSNVTYGFPIMLVLM TAKIVGDVFIEGLYDMHIQL
QSPVFLHWEAPVTSHSLTAREVMSTPVTCLRRREKVGVI VDVLSDTASNHN GFVVEHADDTQPARLQGLILRSQL
IVLLKHKVFVERSNLGLVQRRLRLKDFRDAYPRFPPIQSIHVSQDERECTMDLSEFMNPSPYTVPQEASLPRVFKL
FRALGLRHLVVVDNRNQVVGLVTRKDLARYRLGKRGLEELS LAQT

GenBank Accession No.: AF224741.1, human CLCN7 mRNA complete cds, which provides the nucleic acid sequence (SEQ ID NO: 12):

gccggcgctt cccggccggt gtcgctccgc ggcgggcat ggccaacgtc tctaagaagg tgcctgggtc
cgcccgggac cgggacgacg aggaggcggc gccgctgctg cggaggacgg cgcggcccg cggggggacg

```

ccgctgctga acgggggctgg gcccggggct gcgcgccagt caccacgttc tgcgcttttc cgagtcggac
atatgagcag cgtggagctg gatgatgaac ttttggaccc ggatatggac cctccacatc ccttccccaa
ggagatccca cacaacgaga agctcctgtc cctcaagtat gagagcttgg actatgacaa cagtgagaac
cagctgttcc tggaggagga gcggcggtac aatcacacgg ccttccggac ggtggagatc aagcgctggg
tcatctgcgc cctcattggg atcctcacgg gcctcgtggc ctgcttcatt gacatcgtgg tggaaaacct
ggctggcctc aagtacaggg tcatcaaggg caatatcgac aagttcacag agaaggcgcg actgtccttc
tccctgttgc tgtgggccac gctgaacgcc gccttcgtgc tcgtgggctc tgtgattgtg gctttcatag
agccggtggc tgctggcagc ggaatcccc agatcaagtg cttcctcaac ggggtgaaga tccccacgt
ggtgcggctc aagacgttgg tgatcaaagt gtccggtgtg atcctgtccg tggtcggggg cctggccgtg
ggaaaggaag ggccgatgat ccactcaggt tcagtgattg ccgccgggat ctctcaggga aggtcaacgt
cactgaaacg agatttcaag atcttcgagt acttccgcag agacacagag aagcgggact tcgtctccgc
aggggctgcg gccggagtgt cagcggcggt tggagcccc gtgggtgggg tcctgttcag cttggaggag
ggtgcgtcct tctggaacca gttcctgacc tggaggatct tctttgcttc catgatctcc acgttcaccc
tgaattttgt tctgagcatt taccacggga acatgtggga cctgtccagc ccaggcctca tcaacttcgg
aaggtttgac tcggagaaaa tggcctacac gatccacgag atcccggctc tcatcgccat gggcgtggtg
ggcgggtgtg ttggagctgt gttcaatgcc ttgaactact ggctgaccat gtttcgaatc aggtacatcc
accggccctg cctgcaggtg attgaggccg tgctggtggc cgccgtcacg gccacagttg ccttcgtgct
gatctactcg tcgcgggatt gccagcccct gcaggggggc tccatgtcct acccgctgca gctcttttgt
gcagatggcg agtacaactc catggctgcg gccttcttca acaccccga gaagagcgtg gtgagcctct
tccacgaccc gccaggctcc tacaaccccc tgaccctcgg cctgttcacg ctggtctact tcttcctggc
ctgctggacc tacgggctca cgggtgtctgc cggggtcttc atcccgctcc tgctcatcgg ggctgcctgg
ggccggctct ttgggatctc cctgtcctac ctcacggggg cggcgatctg ggccgacccc ggcaataacg
ccctgatggg agctgctgcc cagctgggcg ggattgtgcg gatgacactg agcctgaccg tcatcatgat
ggaggccacc agcaacgtga cctacggctt ccccatcatg ctggtgctca tgaccgcaa gatcgtgggc
gacgtcttca ttgagggcct gtacgacatg cacattcagc tgcagagtgt gcccttcctg cactgggagg
ccccggtcac ctcacactca ctactgcc a gggaggtgat gagcacacca gtgacctgcc tgaggcgggc
tgagaaggtc ggcgtcattg tggacgtgct gagcgacacg gcgtccaatc acaacggctt ccccggtggtg
gagcatgccg atgacaccca gcctgcccgg ctccagggcc tgatcctgcg ctcccagctc atcgttctcc
taaagcacia ggtgttttgt gagcgggtcca acctgggcct ggtacagcgg cgcctgagge tgaaggactt
ccgagacgcc taccgcgct tcccacccat ccagtccatc cacgtgtccc aggacgagcg ggagtgcacc
atggacctct ccgagttcat gaacccctcc ccctacacgg tgccccagga ggcgtcgctc ccacgggtgt
tcaagctgtt ccgggccctg ggcctgcggc acctggtggt ggtggacaac cgcaatcagg ttgtcgggtt
ggtgaccagg aaggacctcg ccaggtagcg cctgggaaag agaggcttgg aggagctctc gctggcccag
acgtgaggcc cagccctgcc cataatgggc actggcgctg gcaccccggc ccttctgcat ttcctcccgg
agtcactggt ttctcggccc aaaccatgct cccagcagt ggcaatggcg agcacctgc agctgggcgg
gcaggcggca ggcgcggaac tgaccctctc gcgggactga ccctgttgtg ggcagtggte tcccccttg
gcgcctcctt gcgcaggccc agcctccact ctctcgtct aggtttcttt acctccaggg atcagctgtg
tgtgtgtgac ctccctaccg ggctatcggc ctcttgggag ccagcggcag ggccggcacc tgcgtgcctg
tgcccggtgt cgtgagacag agcccttgcc cctgctgctg ccccgagggc tgccctgccc tgggaaggcc
cctctgcctc cacaccagtg gagtcttcga gacttgggag ctgcttggcc tcattttcag ccatgagcag
acggcctgtg gtccctgggc ctgaggcacg gactcgtagc accagggttt ggaggctgcg accgccccgg
agagcagctt cacactggcg ccacagagga gccccacgtg cactccccgg cctgcatccg gcttgggtac
acaggcccag aggactgggg tgactcacgg gccctgtgct gtgatgttga gagctgagaa aaacctcaa
ggccctgagc cccatgccc gccctgcctt ggtcccccaa tcccagagc ttggagtctg ggccccacac
ccagccctgc cttggtccct gagcctcaaa gcgtggaatt gctgccctgt ggacact

```

GenBank Accession No.: AAH68581.1, human OSTM1, which provides the amino acid sequence (SEQ ID NO: 13):

```

MEPGPTAAQR RCSLPPWLPL GLLLWSGLAL GALPFGSSPH RVFHDLLSEQ QLLEVEDLSL SLLQGGGLGP
LSLPPDLPDL DPECRELLLD FANSSAELTG CLVRSARPVR LCQTCYPLFQ QVVSMDNIS RAAGNTSESQ
SCARSLLMAD RMQIVVILSE FFNTTWQEAN CANCLTNNSE ELSNSTVYFL NLFNHTLTCTF EHNLOGNAHS
LLQTKNYSEV CKNCREAYKT LSSLYSEMQK MNELENKAEP GTHLCIDVED AMNITRKLWS RTFNCVPCS
DTPVPIAVSV FILELPVVFY LSSFLHSEQK KRKLILPKRL KSSTSFANIQ ENSN

```

GenBank Accession No.: BC068581.1, human OSTM1 mRNA, which provides the nucleic acid sequence (SEQ ID NO: 14):

```

ggctgtccgc ggtgccggct gggggcggag aggcggcggt gggctccctg ggggtgtgtga gcccggtgat
ggagccgggc ccgacagccg cgcagcggag gtgttcgctt ccgccgtggc tgccgctggg gctgctgctg

```

```

tggtcggggc tggccctggg cgcgctcccc ttccggcagca gtccgcacag ggtcttccac gacctcctgt
cggagcagca gttgctggag gtggaggact tgtccctgtc cctcctgcag ggtggagggc tggggcctct
gtcgctgccc ccggacctgc cggatctgga tcttgagtgc cgggagctcc tgctggactt cgccaacagc
agcgcagagc tgacaggggtg tctgggtgcgc agcgcgccgc ccgtgcgcct ctgtcagacc tgctaccccc
tcttccaaca ggtcgtcagc aagatggaca acatcagccg agccgcgggg aatacttcag agagtcagag
ttgtgccaga agtctcttaa tggcagatag aatgcaaata gttgtgattc tctcagaatt ttttaatacc
acatggcagg aggcaaattg tgcaaattgt ttaacaaaca acagtgaaga attatcaaac agcacagtat
atttccttaa tctattttaat cacaccctga cctgctttga acataacctt cagggggaatg cacatagtct
tttacagaca aaaaattatt cagaagtatg caaaaactgc cgtgaagcat acaaaaactct gagtagtctg
tacagtgaag tgcaaaaaat gaatgaactt gagaataagg ctgaacctgg aacacattta tgcattgatg
tggaagatgc aatgaacatc actcgaaaac tatggagtcg aactttcaac tgttcagtcc cttgcagtga
cacagtgcct gtaattgctg tttctgtggt cattctcttt ctacctgttg tcttctacct tagtagcttt
cttcactcag agcaaaagaa acgcaaactc attctgccc aacgtctcaa gtccagtacc agttttgcaa
atattcagga aaattcaaac tgagacctac aaaatggaga attgacatat cacgtgaatg aatggtggaa
gacacaactt ggtttcagaa agaagataaa ctgtgatttg acaagtcaag ctcttaagaa atacaaggac
ttcagatcca tttttaaata agaattttcg atttttcttt ctttttccac ttctttctaa cagatttgga
tattttttaat ttccaggcat agcagtgtta tctattttta tgtgtatttg tcacaataac agaacatgca
agaacaatca ttattttatt ttataggcat ttgattacta ttctagactt ctggtatctt cttactaaca
taagtatctc aagtagaaaa gtttttgaaa actaacattt aaaaattaat cagttacagt aaagactttg
aaaaagaaat gtacttgtaa ggaagtagct taattacccc ccattgcagt attattgtta tatatatagt
taatatgttg tacatcacia taatatataa ttcagtctct agtttcccta gagtcatttt tgaaaccact
gattgcaaac ctccctgaca atttttaaaa gtagtaagcc acattacatt tatctttgta aaaagattta
tggttaactgg tttcttactt gacttttata aatagtattt tacatcttat ttttgccttt atttcataag
taatttaaaa atcactggat tgctttatta tattcagggc aatatggatt atttttatac caaggatttg
catcgtgaat taaattaagt tatttggtgcaa ttataaattt attactactt taaatcaaat gtagcattat
cacactgtat ttaaattgtc atttttttaa ggaatatatt cttcttaaga tatatagagg attttgaggaga
agagagacag gaggggtaaa accagcttaa ggttcagcga gcagaaaggg acctgagagg atgctcactg
taagactgtt ggacagtggg gtgtattgag gggatgaatc ggaacgatag tctcatgcag aaaatagtga
gattaagatc atccttattg tttctaaatt atttcaatca gatgaaagtg atacgattga aatgaaatca
catagttcgt gctcagaaat tctatttttg tatgtttgta ttagccttta gaaaaaacac tccgtttcag
aattgttcac agttttattt cttagggttt tagagttcag gatttcattt attaatctt tcttgctttt
ttggtggaaa taggctttgt tgtaaacatt aagaatataa aatctcctct atatagaaac aagaattttg
ttaaaaagag aatttgaatc ctttcctata ctataaaatg ctctataggg agacaaagtg tttctttttt
cttttatgtt tactgtttat gtggagtga atataaggct cttggatgta taacatactc aaaagctgtt
acactttctc tgatctgctg tgatccactg aaaatgtgct ggggtttgtt ctgctgtcac tgtttatgct
gctggaactt agcactgtct tgatttgaag catatgattg agagccattt gaagcaatct tcattaatgc
agataaaaca agtttacatg tgcagagtta gaaaatgaca tgttcaattc tgtaagtggg gactttttga
gcacctttca gtattatgta tttgtaaaaa ccattgtttt tggatataaa gctaataagc acttttaaaaa
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagaaaaa aaaaaaaaa

```

GenBank Accession No.: AAG00797.1, human MCOLN1, which provides the amino acid sequence (SEQ ID NO: 15):

```

MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKYFFMSPCDKFRAKGRKPCKLMLQVVKILVV
TVQLILFGLSNQLAVTFREENTIAFRHLFLLGYSDGADDTFAAYTREQLYQAI FHAVDQYLALPDVSLGRYAYVRG
GGDPWTNGSGLALCQRYYHRGHVDPANDTFDIDPMVVTDCIQVDPPPERPPPPPSDDLTLLESSSSYKNLTLKFHKL
VNVTIHFRLKTINLQSLINNEIPDCYTFSVLITFDNKAHSGRIPI SLETQAHIQECKHPSVVFQHGDNFRLLFDVV
VILTCSLSFLLCARSLLRGFLLQNEFVGFMWRQRGRVISLWERLEFVNGWYILLVTSVDVLTISGTIMKIGIEAKNL
ASYDVCSILLGTSTLLVWGVIRYLTFHFNYNIL IATLRVALPSVMRFCCCVAVIYLG YCFCGWIVLGPYHVKFRS
LSMVSECLFSLINGDDMFVTFAMQAQQGRSSLVWLFSQLYLYSFISLFIYMVLSLFIALITGAYDTIKHPGGAGA
EESELQAYIAQCQDSPTSGKFRRGSGSACSLCCCGRDPSEEHSLLVN

```

GenBank Accession No.: AF287269.1, human MCOLN1 mRNA, complete cds, which provides the nucleic acid sequence (SEQ ID NO: 16):

```

agatcagctg atgccggagg gtttgaagcc gcgccgcgag ggagcgaggt cgcagtgaca gcggcgggcg
atcggaacca ggctgccccg ccgtaccgcg ctgcgtcccg cgctcccgcc ccagcatgac agccccggcg
ggtccgcgcg gctcagagac cgagcggtct ctgaccccca accccgggta tgggacctag gcggggcctt
caccggcccc tccgacaccc ccagaagagg aagaccttcg ccgtcgtctc aaatactttt tcatgagtcc
ctgcgacaag tttcgagcca agggccgcaa gccctgcaag ctgatgctgc aagtgggtcaa gatcctgggtg

```

```

gtcacggtgc agctcatcct gtttgggctc agtaatcagc tggctgtgac attccgggaa gagaacacca
tcgccttccg acacctcttc ctgctgggct actcggacgg agcggatgac accttcgcag cctacacgcg
ggagcagctg taccaggcca tcttccatgc tgtggaccag tacctggcgt tgctgacgt gtcactgggc
cggtatgcgt atgtccgtgg tgggggtgac ccttggacca atggctcagg gcttgctctc tgccagcggc
actaccaccg aggccacgtg gacccggcca acgacacatt tgacattgat ccgatgggtg ttactgactg
catccagggtg gatccccccg agcggccccc tccgcccccc agcgacgacg tcaccctctt ggaaagcagc
tccagttaca agaacctcac gctcaaattc cacaagctgg tcaatgtcac catccacttc cggctgaaga
ccattaacct ccagagcctc atcaataatg agatcccgga ctgctatacc ttcagcgtcc tgatcacgtt
tgacaacaaa gcacacagtg ggcggatccc catcagcctg gagacccagg cccacatcca ggagtgtgag
caccacagtg tcttccagca cggagacaac agcttccggc tcctgtttga cgtgggtggc atcctcacct
gctccctgtc cttcctcctc tgcgcccgtc cactccttcg aggcttctg ctgcagaacg agtttgtggg
gttcatgtgg cggcagcggg gacgggtcat cagcctgtgg gagcggctgg aatttgtcaa tggctggtac
atcctgctcg tcaccagcga tgtgtcacc atctcgggca ccatcatgaa gatcggcatc gaggccaaga
acttggcgag ctacgacgtc tgcagcatcc tcctgggcac ctcgacgctg ctggtgtggg tgggctgat
ccgctacctg accttcttcc acaactacaa tatectcatc gccacactgc gggtgccct gccagcgtc
atgcgcttct gctgctgcgt ggctgtcatc tacctgggct actgcttctg tggctggatc gtgctggggc
cctatcatgt gaagtccgc tcaactctca tgggtgtctga gtgcctgttc tcgctcatca atggggacga
catgtttgtg acgttcgccg ccatgcaggc gcagcagggc cgcagcagcc tgggtgtggc cttctcccag
ctctaccttt actccttcat cagcctcttc atctacatgg tgctcagcct cttcatcgcg ctcatcaccg
gcgcctacga caccatcaag catcccggcg gcgcaggcgc agaggagagc gagctgcagg cctacatcgc
acagtgccag gacagcccca cctccggcaa gttccgccgc gggagcggct cggcctgcag ccttctctgc
tgctgcggaa gggacccctc ggaggagcat tcgctgctgg tgaattgatt cgacctgact gccgttgagc
cgtaggccct ggactgcaga gacccccgcc cccgaccccg cttatttatt tgtagggttt gcttttaagg
atcggctccc tgtcgcgcc gaggagggcc tggaccttcc gtgtcggacc cttgggggcg gggagactgg
gtggggaggg tgttgaataa a

```

GenBank Accession No.: Q68CP4.2, human HGSNAT, which provides the amino acid sequence (SEQ ID NO: 17):

```

MTGARASAAE QRRAGRSGQA RAAERAAGMS GAGRALAALL LAASVLSAAL LAPGGSSGRD AQAAPPRDL
KKRHAELKMD QALLLIHNEL LWTNLTVYWK SECCYHCLFQ VLVNVPQSPK AGKPSAAAAS VSTQHGSILQ
LNDTLEEKEV CRLEYRFGEF GNYSLLVKNI HNGVSEIACD LAVNEDPVDS NLPVSIAFLI GLAVIIVISF
LRLLLSLDDF NNWISKAISS RETDRLINSE LGSPSRTDPL DGDVQPATWR LSALPPRLRS VDTFRGIALI
LMVFNNGGG KYWYFKHASW NGLTVADLVF PWFVFIMGSS IFLSMTSILQ RGCSKFRLLG KIAWRSFLLI
CIGIIIVNPN YCLGPLSWDK VRIPGVLQRL GVTYFVAVL ELLFAKPVPE HCASERSCLS LRDITSSWPQ
WLLILVLEGL WLGLTFLLPV PGCPTGYLGP GGIGDFGKYP NCTGGAAGYI DRLLLGDDHL YQHPSSAVLY
HTEVAYDPEG ILGTINSIVM AFLGVQAGKI LLYKARTKD ILIRFTAWCC ILGLISVALT KVSENEGFIP
VNKNLWSLSY VTTLSFAFF ILLVLYPVVD VKGLWTGTPF FYPGMNSILV YVGHEVFENY FPFQWKLKDN
QSHKEHLTON IVATALWVLI AYILYRKKIF WKI

```

GenBank Accession No.: NM_152419, human HGSNAT mRNA, which provides the nucleic acid sequence (SEQ ID NO: 18):

```

agggcggggc gcagcgggca ggcaagggcg gccgagcggg cggcgggcat gagcggggcg ggcagggcgc
tgggcgcgct gctgctggcc gcgtccgtgc tgagcgccgc gctgctggcc cccggcggtc cttcggggcg
cgatgcccag gccgcgccgc cagcagactt agacaaaaaa agacatgcag agctgaagat ggatcaggct
ttgctactca tccataatga acttctcttg accaacttga ccgtctactg gaaatctgaa tgctgttata
actgcttggt tcaggttctg gtaaacgttc ctcagagtcc aaaagcaggg aagcctagtg ctgcagctgc
ctctgtcagc acccagcagc gatctatcct gcagctgaac gacaccttgg aagagaaaga agttttagg
ttggaataca gatttgagga atttggaaac tattctctct tggtaaagaa catccataat ggagttagtg
aaattgcctg tgacctggct gtgaacgagg atccagttga tagtaacctt cctgtgagca ttgcattcct
tattggtctt gctgtcatca ttgtgatata ctttctgagg ctcttggtga gtttgatga ctttaacaat
tggaatttcta aagccataag ttctcgagaa actgatcgcc tcatcaattc tgagctggga tctcccagca
ggacagaccc tctcgatggg gatgttcagc cagcaacgtg gcgtctatct gccctgccgc cccgcctccg
cagcgtggac accttcaggg ggattgctct tatactcatg gtctttgtca attatggagg aggaaaatat
tggtacttca aacatgcaag ttggaatggg ctgacagtgg ctgacctcgt gttcccgtgg tttgtattta
ttatgggatc ttccattttt ctatcgatga cttctatact gcaacggggg tgttcaaaat tcagattgct
ggggaagatt gcatggagga gtttcctgtt aatctgcata ggaattatca ttgtgaatcc caattattgc
cttgggtccat tgtcttggga caaggtgcgc attcctggtg tgctgcagcg attgggagtg acatactttg

```

tggttgctgt	gttggagctc	ctcttttgcta	aacctgtgcc	tgaacattgt	gcctcggaga	ggagctgcct
ttctcttcga	gacatcacgt	ccagctggcc	ccagtggctg	ctcatcctgg	tgctggaagg	cctgtggctg
ggcttgacat	tcctcctgcc	agtccctggg	tgccctactg	gttatccttg	tcctgggggc	attggagatt
ttggcaagta	tccaaattgc	actggaggag	ctgcaggcta	catcgaccgc	ctgctgctgg	gagacgatca
cctttaccag	cacccatctt	ctgctgtact	ttaccacacc	gaggtggcct	atgaccccga	gggcatcctg
ggcaccatca	actccatcgt	gatggccttt	ttaggagttc	aggcaggaaa	aatactattg	tattacaagg
ctcggaccaa	agacatcctg	attcgattca	ctgcttggtg	ttgtattctt	gggctcattt	ctgttgctct
gacgaagggt	tctgaaaatg	aaggctttat	tccagtaaac	aaaaatctct	gggccctttc	gtatgtcact
acgctcagtt	cttttgccct	cttcacccctg	ctggctcctg	accagtttgt	ggatgtgaag	gggctgtgga
caggaacccc	attcttttat	ccaggaatga	attccattct	ggtatatgtc	ggccacgagg	tgtttgagaa
ctacttcccc	tttcagtggg	agctgaagg	caaccagtcc	cacaaggagc	acctgactca	gaacatcgtc
gccactgccc	tctgggtgct	cattgcctac	atcctctata	gaaagaagat	tttttggaag	atctgatggc
tcctactgag	atgtgctgct	ggaagactct	agtaggcctg	cagggaggag	tgaagcagcc	tttgtaaag
ggaagcattc	attaggaaat	tgactggctg	cgtgtttaca	gactctgggg	gaagacactg	atgtcctcaa
actggttaac	tgtgacacgg	ctcgccagaa	ctctgcctgt	ctatgtgtga	cttacagatt	tgaaatgtaa
ttgtcttttt	tcctccatct	tctgtggaaa	tggatgtctt	tggaaactca	ttccgaggag	ataagcttta
actttccaaa	agggaattgc	catgggtgtt	tttcttctgt	ggtgagtga	acaatctgag	gtctggttct
tgctgacctt	gttgccctgc	aaacttcctt	tccacgtgta	cgcgacaccc	aacacgaaat	gccatcactc
ctactgcggc	tgctatgaag	cttactgggt	gtgatgtgtt	ataatttagt	ctgttttttt	gattgaatgc
agtttaaatgt	ttccagaaag	ccaaagtaat	tttcttttca	gatatgcaag	gctttgggtg	gtccaaaaaa
tgtctatcac	aagccatttt	ttccttttcc	tctctcgaaa	agttaaaata	tctatgtgtt	attcccaaac
cctcttacct	atgtatctgc	ctgtctgtcc	atcatcttcc	ttcctcccta	tctctgtgta	tctggatggc
agccgctgcc	caggggagtg	gctgtgggga	gggcaggtag	tgtctttgcc	tggtgggtcca	gctgagccat
ccctgctggg	tgatgctggg	caagaccctt	ggcccgctctg	ggccttggtg	tcctcacttg	tgaaatgagc
gggaagatga	ctctcagttc	cttccacctc	ttagacatgg	tgaggtaaca	gacatcaaaa	gcttttctga
aatcttcaga	agaaatagtt	ccattacaga	aaactcttca	aaataaatag	tagtgaaaac	ttttaaaaaa
tctcattgga	gtaagtcttt	tcaagatgat	cctccacaat	ggaggcagcg	ttcctacttg	tcatcacaca
gctgaagaca	ttgtttctta	gggtgtgaaat	cggggacaaa	ggacaaacag	agacacacgg	cattgttcat
gggaggcatc	gtcaccctcc	tgggtgttct	gtgggaattt	cctgtgtgag	gaaaacgtgg	ccacaggggt
gtgctgtacc	cacccttccc	cggcgagatg	gccctcggcc	tgtgccgctg	cttccaccct	cgccactcca
tggcagcttt	tggctctgtt	ccggctctgc	cctctgccct	gaactctcat	ccggcttgta	cctgcctgct
ggaccctcc	acctggaggc	cagcccatgt	ctcaggccca	gccctagcct	cttctcctca	aattctaagt
gttttctctt	taggtttccc	tggctttgtg	aatggatcat	gtgtctctag	gtataaacct	gacatcatct
ttccaccctg	cttacctcca	ccagatctcc	ccagttctgt	ctccatcttc	tacctgcagc	tgctctgttc
tcatggtcac	tgctgcatca	ctgagtctgg	acccttggtt	tcattttcaa	actggcctcc	ttccctcggt
ccccacttct	taaagtcacc	tgtccattgc	caccagatta	agctttctcc	agccagatca	cctctctctg
agaaacctcc	attgacatgg	aaacaccatt	gtctggcaca	catactcaca	tactcacctt	cccgtcttga
tccccacaca	tctttccagc	ctcccttccc	actccactcc	ctgctctctc	ctccacctcc	ccatcctctt
gtctcccttc	ccctctgaat	ccagcccagc	ggggcttctc	ctgcctccat	cacatcacag	aagtacctcc
tgcttctggt	tttaattaga	gccttccccc	attacatttt	cctctgaatt	ttttcctatc	tacatttgat
ctgtcatgtt	taaacccctt	acttctaagg	gaacttctct	aatctcttat	cctcatcccc	aaatagtgtt
ttcttcctct	gggttcttat	aatgttggta	tcaatctcac	agcatttagt	gcttcctgcc	tgggtgtgaca
gttacctgtg	tgcatgtgca	atthtctaatt	tcccacgcta	gactgtgagc	ttcctaaggc	aagaatcatg
ccttgttggt	ttctgtattc	ctcatgggtg	caaacacagt	gccttctaca	ttgcaggcgc	tgaataaaca
ttttttaaagc	aaaatgatgt	ggattttttaa	aataaaatatt	taagtgtctg	taagatgagc	atgtatccgg
ggtgcccattg	aaatgttctt	ggggccgtgt	ggggacagtc	gtcattcctc	ctcctgccac	ccttttcttt
cagtgaagtca	ctgtggatgg	tcccagctgt	gtcatcccaa	agttcagcag	ggaaagctga	gctgggcctc
tccagggtgag	ttttctagaa	gcatttctca	aactgtgggt	tacatcaact	tgggtgtctt	gagctgtaag
gaaggaaactc	cggagtcagc	tgggctacag	gggagcttct	ctaagtcctg	cgggaggcca	gaccagcct
gagcttgctg	ttagctagcg	gaggcagctg	ctgggtggccc	aggtgctcga	caccaggcat	cccctctcct
cccacgaagg	gtgtgccata	atcccccttca	acaggaaatg	cttcccagaa	gcctctcagc	agcctccctt
cctgtcctat	cagctagaag	cgcctcgctt	gtcccaagac	cagcagggac	agggaactgt	ccgagcccgt
ggctgtgtgg	aggaaggcga	cccccagcac	aagattgggt	tcctttggga	agggaagagg	gagtgtgttg
gggtaagggg	tagagcagag	gaatgggtcag	ggggcaacaa	ccgctgacag	ctgcaacagg	tgcattggcat
ctcacaggga	ggcaggagg	tgcgagctcc	taagtaatgg	agcaaaaaaa	ttctattctg	tagaatgggg
agagaaaatg	tgacatttta	atthtctttt	gcatttata	tcctaattcc	tacttaaagt	gaatatactg
ccgctgtaga	tcataaaatg	tatcttttcc	atggccaaca	aggggcatct	tttataaatg	cataataacc
cagtttgtat	caaaggggat	cgacttaagt	gaaatttcaa	catgctgtta	ctttttcctt	ttaatgtaat
tctgttttcc	aaataaatgg	gggagacaaa	tggaaaaaaa	aaaaaaa		

GenBank Accession No.: AAB63982.1, human NPC1, which provides the amino acid sequence (SEQ ID NO: 19):

MTARGLALGLLLLLLCPAQVFSQSCVWYGECEGIAYGDKRYNCEYSGPPKPLPKDGYDLVQELCPGFFFGNVSLCCD
VRQLQTLKDNLQLPLQLFLSRCPSCFYNNLLNLFCELTCSPRQSQFLNVTATEDYVDPVTNQTNTNVKELQYYVGQSF
ANAMYNACRDVEAPSSNDKALGLLCGKDADACNATNWIEYMFNKDNGQAPFTITPVFSDFPVHGMEPMNNATKGCD
ESVDEVTAPCSCQDCSIVCGPKPQPPPPAPWTILGLDAMYVIMWITYMAFLLVFFGAFFAVWCYRKRYFVSEYTP
IDSNIAFSVNASDKGEASCCDPVSAAFEGCLRRLFTRWGSFCVRNPGCVIFFSLVFITACSSGLVFRVTNPNVDL
WSAPSSQARLEKEYFDQHFQPFERTEQLIIRAPLTDKHIYQPYPSGADVFPFGPPLDIQILHQVLDLQIAIENITAS
YDNETVTLQDICLAPLSPYNTNCTILSVLNYFQNSHSLVDHKKGDDFFVYADYHTHFLYCVRAPASLNDTSLLDHP
CLGTFGGPVFPWLVLGGYDDQNYNNATALVITFPVNNYYNDTEKLQRAQAWKEKEFINFVKNYKNPNLTISFTAERS
IEDELNRESDSVFTVVISYAIMFLYISLALGHIKSCRLLVDSKVS LGIAGILIVLSSVACSLGVFSYIGLPLTL
IVIEVIPFLVLAVGVDNIFILVQAYQORDERLQGETLDQQLGRVLGEVAPSMFLSSFSETVAFFLGALSVMFAVHTF
SLFAGLAVFIDFLLQITCFVSLGLDIKRQEKNRDLIFCCVRGAEDGTSVQASESCLFRFFKNSYSPLLLKDWMRP
IVIAIFVGVLSFSIAVLNKVDIGLDQSLSDNPNPKCGKGGHAAYS SAVNILLGHGTRVGATYFMTYHTVLQTSADFIDALKKARLIASN
VTETMGINGSAYRVFPYSVFYVFYEQYLTIIIDDTIFNLGVSLGAI FLVTMVLLGCELWSAVIMCATIAMVLVNMFG
VMWLWGISLNAVSLVNLVMSCGISVEFCSHITRAFTVSMKGS RVERAEALAHMGSSVFSGITLT KFGGIVVLAF
KSQIFQIFYFRMYLAMVLLGATHGLIFLPVLLSYIGPSVNKAKSCATEERYKGTERRERLLNF

GenBank Accession No.: AF002020.1, human NPC1 mRNA, complete cds, which provides the nucleic acid sequence (SEQ ID NO: 20):

tttgctcctg	ctcctccgct	cctcctgcgc	gggggtgctga	aacagcccgg	ggaagtagag	ccgcctccgg
ggagcccaac	cagccgaacg	ccgccggcgt	cagcagcctt	gcgcggccac	agcatgaccg	ctcgcggcct
ggcccttggc	ctcctcctgc	tgtactgtg	tccagcgcag	gtgtttttcac	agtcctgtgt	ttgggtatgga
gagtgtggaa	ttgcatatgg	ggacaagagg	tacaattgcg	aatatttctgg	cccaccaaaa	ccattgccaa
aggatggata	tgacttagtg	caggaactct	gtccaggatt	cttcttttggc	aatgtcagtc	tctgtttgtga
tgttcggcag	cttcagacac	taaaagacaa	cctgcagctg	cctctacagt	ttctgtccag	atgtccatcc
tgtttttata	acctactgaa	cctgttttgt	gagctgacat	gtagccctcg	acagagtcag	tttttgaatg
ttacagctac	tgaagattat	gttgatcctg	ttacaaacca	gacgaaaaca	aatgtgaaag	agttacaata
ctacgtcggg	cagagttttg	ccaatgcaat	gtacaatgcc	tgccgggatg	tggaggcccc	ctcaagtaat
gacaaggccc	tgggactcct	gtgtgggaag	gacgctgacg	cctgtaatgc	caccaactgg	attgaataca
tgttcaataa	ggacaatgga	caggcacctt	ttaccatcac	tcctgtgttt	tcagattttc	cagtccatgg
gatggagccc	atgaacaatg	ccaccaaagg	ctgtgacgag	tctgtggatg	aggtcacagc	accatgtagc
tgccaagact	gctctattgt	ctgtggcccc	aagccccagc	ccccacctcc	tcctgctccc	tggacgatcc
ttggccttga	cgccatgtat	gtcatcatgt	ggatcaccta	catggcgttt	ttgcttgtgt	tttttggagc
atttttttgca	gtgtgggtgct	acagaaaacg	gtatttttgtc	tccgagtaca	ctcccatcga	tagcaatata
gcttttttctg	ttaatgcaag	tgacaaaagga	gaggcgctct	gctgtgaccc	tgtcagcgca	gcatttgagg
gctgcttgag	gcggctgttc	acacgctggg	ggtcttttctg	cgcccgaaac	cctggctgtg	tcatttttctt
ctcgctggtc	ttcattactg	cgtgttcgtc	aggcctgggt	tttgtccggg	tcacaaccaa	tccagttgac
ctctggtcag	cccccagcag	ccaggctcgc	ctggaaaaag	agtactttga	ccagcacttt	gggcctttct
tccggacgga	gcagctcatc	atccggggccc	ctctcactga	caaacacatt	taccagccat	acccttcggg
agctgatgta	cccttttgac	ctccgcttga	catacagata	ctgcaccagg	ttcttgactt	acaaatagcc
atcgaaaaca	ttactgcctc	ttatgacaat	gagactgtga	cacttcaaga	catctgcttg	gcccctcttt
caccgtataa	cacgaactgc	accatttttga	gtgtgttaaa	ttacttccag	aacagccatt	ccgtgctgga
ccacaagaaa	ggggacgact	tcttttgtga	tgccgattac	cacacgcact	ttctgtactg	cgtacgggct
cctgcctctc	tgaatgatac	aagtttgtctc	catgaccctt	gtctgggtac	gtttgggtgga	ccagtgttcc
cgtggccttg	gttgggaggc	tatgatgatc	aaaactacaa	taacgccact	gcccttgtga	ttaccttccc
tgtcaataat	tactataatg	atacagagaa	gctccagagg	gcccaggcct	gggaaaaaga	gtttattaat
tttgtgaaaa	actacaagaa	tcccaatctg	accatttctc	tcactgctga	acgaagtatt	gaagatgaac
taaatcgtga	aagtgcacagt	gatgtcttca	ccgttgtaat	tagctatgcc	atcatgtttc	tatatatttc
cctagccttg	gggcacatca	aaagctgtcg	caggcttctg	gtggattcga	aggtctcact	aggcatcgcg
ggcatcttga	tcgtgctgag	ctcgggtggc	tgctccttgg	gtgtcttcag	ctacattggg	ttgcccttga
ccctcattgt	gattgaagtc	atcccgttcc	tgggtgctggc	tgttggagtg	gacaacatct	tcattctggg
gcaggcctac	cagagagatg	aacgtcttca	aggggaaacc	ctggatcagc	agctgggcag	ggtcctagga
gaagtggctc	ccagtatgtt	cctgtcatcc	ttttctgaga	ctgtagcatt	tttcttagga	gcattgtccg
tgatgccagc	cgtgcacacc	ttctctctct	ttgcgggatt	ggcagtcttc	attgactttc	ttctgcagat
tacctgtttc	gtgagtctct	tgggggttaga	cattaaacgt	caagagaaaa	atcggctaga	catcttttgc

```

tgtgtcagag gtgctgaaga tggacaaga gtccaggcct cagagagctg tttgtttcgc ttcttcaaaa
actcctattc tccacttctg ctaaaggact ggatgagacc aattgtgata gcaatatttg tgggtgttct
gtcattcagc atcgcagtc tgaacaaagt agatattgga ttggatcagt ctctttcgat gccagatgac
tcctacatgg tggattatth caaatccatc agtcagtacc tgcagtcggg tccgcctgtg tactttgtcc
tggaggaagg gcacgactac acttcttcca aggggcagaa catggtgtgc ggccgcatgg gctgcaacaa
tgattccctg gtgcagcaga tatttaacgc ggccgagctg gacaactata cccgaatagg ctctgcccc
tcgtcctgga tcgacgatta tttcgactgg gtgaagccac agtcgtcttg ctgtcgagtg gacaatatca
ctgaccagtt ctgcaatgct tcagtgggtg accctgcctg cgttcgctgc aggcctctga ctccggaagg
caaacagagg cctcaggggg gagacttcat gagattcctg cccatgttcc tttcggataa ccctaacccc
aagtgtggca aagggggaca tgctgcctat agttctgcag ttaacatcct ccttggccat ggcaccaggg
tcggagccac gtacttcatg acctaccaca ccgtgctgca gacctctgct gactttattg acgctctgaa
gaaagcccga cttatagcca gtaatgtcac cgaaaccatg ggcattaacg gcagtgccta ccgagtatth
ccttacagtg tgttttatgt cttctacgaa cagtacctga ccatcattga cgacactatc ttcaacctcg
gtgtgtccct gggcgcgata tttctgggtg ccatggctct cctgggctgt gagctctggg ctgcagtcac
catgtgtgcc accatcgcca tggctctggg caacatgtth ggagtthtgt ggctctgggg catcagtcctg
aacgctgtat ccttgggtcaa cctgggtgat agctgtggca tctccgtgga gttctgcagc cacataacca
gagcgttcac ggtgagcatg aaaggcagcc gcgtggagcg cgcggaagag gcacttgccc acatgggcag
ctccgtgttc agtggaatca cacttacaaa atttggaggg attgtgggtg tggcttttgc caaatctcaa
atthttccaga tattctactt caggatgtat ttggccatgg tcttactggg agccactcac ggattaatat
ttctccctgt cttactcagt tacatagggc catcagtaaa taaagccaaa agttgtgcca ctgaagagcg
atacaaagga acagagcgcg aacggcttct aaatttctag ccctctcgca gggcatcctg actgaactgt
gtctaagggg cggtcggtth accactggac ggggtgctgca tcggcaaggc caagttgaac accggatggg
gccaaccatc ggttgthttgg cagcagctth gaacgtagcg cctgtgaact caggaatgca cagttgactt
gggaagcagt attactagat ctggaggcaa ccacaggaca ctaaacttct cccagcctct tcaggaaaga
aacctcattc tttggcaagc aggaggtgac actagatggc tgtgaatgtg atccgctcac tgacactctg
taaaggccaa tcaatgcact gtctgtcctc tcctthtttag gagtaagcca tcccacaagt tctataccat
atthtttagtg acagttgagg ttgtagatac actthtataac atthttatagt ttaaagagct ttattaatgc
aataaattaa cthttgtacac atthtttatat aaaaaaacag caagtgattt cagaatgttg taggcctcat
tagagcttgg tctccaaaaa tctgtthtgaa aaaagcaaca tgttcttcac agtgthtccc tagaaaggaa
gagattthaat tgccagttag atgtggcatg aaatgaggga caaagaaagc atctcgtagg tgtgtctact
gggtthttaa ttatthtttct ttaataaaat acattgttht ctaaaaaaaa aaa

```

GenBank Accession No.: CAA54416.1, human LAMP-2A, which provides the amino acid sequence (SEQ ID NO: 21):

```

MVCFRLFPVP GSGLVLVCLV LGAVRSYALE LNLTDSENA CLYAKWQMN TVRYETTNKT YKTVTISDHG
TVTYNGSICG DDQNGPKIAV QFGPGFSWIA NFKAASTYS IDSVSFSYNT GDNTTFPDAE DKGILTVDEL
LAIRIPLNDL FRCNSLSTLE KNDVVQHYWD VLVQAFVQNG TVSTNEFLCD KDKTSTVAPT IHTTVPSPTT
TPTPKEKPEA GTYSVNNGND TLLATMGLQ LNTQDKVAS VININPNTTH STGSCRSHA LLRLNSSTIK
YLDVFVAVKN ENRFYLKEVN ISMYLVNGSV FSIANNLSY WDAPLGSSYM CNKEQTVSVS GAFQINTFDL
RVQPFNVTOG KYSTAQDCSA DDDNFLVPIA VGAALAGVLI LVLLAYFIGL KHHHAGYEQF

```

GenBank Accession No.: X77196.1, human LAMP2 mRNA, which provides the nucleic acid sequence (SEQ ID NO: 22):

```

ccgattcctg gctthttgcaa ggctgtgggc ggtggctcatc agtgcctctg acccagggtcc agcgagcctt
ttccctgggtg ttgcagctgt tgttgtagcg ccgccgtcgc cgcgcgtcgc gcctgctctg cgggggtcatg
gtgtgcttcc gcctcttccc ggttccgggc tcagggtctg ttctggctct cctagtcctg ggagctgtgc
ggtcttatgc attggaactt aatttgacag attcagaaaa tgccacttgc cthttatgcaa aatggcagat
gaatttcaca gtacgctatg aaactacaaa taaaacttat aaaactgtaa ccatttcaga ccatggcact
gtgacatata atggaagcat ttgtggggat gatcagaatg gtcccaaaat agcagtgcag ttcggacctg
gctthttcctg gattgagaat tttaccaagg cagcatctac ttattcaatt gacagcgtct cattthtcta
caacactggg gataacacaa catttctctga tgctgaagat aaaggaattc ttactgttga tgaactthttg
gccatcagaa ttccattgaa tgacctthtt agatgcaata gthttatcaac tttggaaaag aatgatgttg
tccaacacta ctgggatgtt cttgtacaag cthttgtcca aaatggcaca gtgagcacia atgagthtctt
gtgtgataaa gacaaaactt caacagtggc acccaccata cacaccactg tgccatctcc tactacaaca
cctactccaa aggaaaaacc agaagctgga acctattcag ttaataatgg caatgatact tgtctgctgg
ctaccatggg gctgcagctg aacatcactc aggataagggt tgcttcagtt attaacatca accccaatac
aactcactcc acaggcagct gccgttctca cactgctcta cttagactca atagcagcac cattaagtat
ctagacttht tctthtgctgt gaaaaatgaa aaccgattth atctgaagga agtgaacatc agcatgtatt

```

```

tggttaatgg ctccgttttc agcattgcaa ataacaatct cagctactgg gatgcccccc tgggaagttc
ttatatgtgc aacaaagagc agactgtttc agtgtctgga gcatttcaga taaatacctt tgatctaagg
gttcagcctt tcaatgtgac acaaggaaag tattctacag ctcaagactg cagtgcagat gacgacaact
tccttgtgcc catagcgggtg ggagctgcct tggcaggagt acttatttcta gtgttgctgg cttattttat
tgggtctcaag caccatcatg ctggatatga gcaattttag aatctgcaac ctgattgatt atataaaaat
acatgcaaat aacaagattt tcttacctct cagttgttga aacactttgc ttcttaaaat tgatatgttg
aaactttaat tcttttatca atcccagcat tttgagatca gtctttatta ataaaacctg ttctctttaa
tcagcttaaa atccaaagtg tcatatttac tggtcctgga gacaaacttg ttcaaaagaa catcaacgtg
caatgtttta aggtctatct taagaagccc tggccaaatt ttgatcctaa ccttgaagta tgccttgaac
ttattaacat ggccattata agaataaaat atgtagtgtg gtcttaatgg aattaataaa tgtcatttca
ctactggtgt tctgttttca atgtataagg actatagtga tttaaactca tcaatgtgcc tttgcataaa
gttgattaaa taaatattga tgtggtataa atgcccatca gatatgct

```

GenBank Accession No.: AAA91149.1, human LAMP-2B, which provides the amino acid sequence (SEQ ID NO: 23):

```

MVCFRLEFPVPGSGLVLVCLVLGAVRSYALELNLTDSENATCLYAKWQMNFTVRYETTNKTYKTVTISDHGTVTYNG
SICGDDQNGPKIAVQFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFPDAEDKGILTVDELLAIRIPLNDLFR
CNSLSTLEKNDVVQHYWDVLVQAFVQNGTVSTNEFLCDKDKTSTVAPTIHTTVPSPTTTPKEKPEAGTYSVNNG
NDTCLLATMGLQLNITQDKVASVININPNTTHSTGSCRSHALLRLNSSTIKYLDFFVFAVKNNRFFYLKEVNISMY
LVNGSVFSIANNLSYWDAPLGSSYMCNKEQTVSVSGAFQINTFDLRVQPFNVTQGKYSTAQECSLDDDTILIPII
VGAGLSGLIIVIVIAVYVIGRRKSYAGYQTL

```

GenBank Accession No.: U36336.1, human LAMP-2B mRNA, complete cds, which provides the nucleic acid sequence (SEQ ID NO: 24):

```

ccgattcctg gcttttgcaa ggctgtggtc ggtggtcatc agtgcctctt acccaggtcc agcgagcctt
ttccctgggtg ttgcagctgt tgttgtaccg ccgccgtcgc cgccgtcgcg gcctgctctg cgggggtcatg
gtgtgcttcc gectcttccc ggttccgggc tcagggtctg ttctggctct cctagtcctg ggagctgtgc
ggctcttatgc attggaactt aatttgacag attcagaaaa tgccacttgc ctttatgcaa aatggcagat
gaatttcaca gtacgctatg aaactacaaa taaaacttat aaaactgtaa ccatttcaga ccatggcact
gtgacatata atggaagcat ttgtggggat gatcagaatg gtcccaaaat agcagtgcag ttccggacctg
gcttttcctg gattgcgaat tttaaccaagg cagcatctac ttattcaatt gacagcgtct cattttccta
caacactggg gataacacaa catttcctga tgctgaagat aaaggaattc ttactgttga tgaacttttg
gccatcagaa ttccattgaa tgaccttttt agatgcaata gtttatcaac tttggaaaag aatgatgttg
tccaacacta ctgggatgtt cttgtacaag cttttgtcca aaatggcaca gtgagcacia atgagttcct
gtgtgataaa gacaaaactt caacagtggc acccaccata cacaccactg tgccatctcc tactacaaca
cctactccaa aggaaaaacc agaagctgga acctattcag ttaataatgg caatgatact tgtctgctgg
ctaccatggg gctgcagctg aacatcactc aggataaggt tgcttcagtt attaacatca accccaatac
aactcactcc acaggcagct gccgttctca cactgctcta cttagactca atagcagcac cattaagtat
ctagactttg tctttgctgt gaaaaatgaa aaccgatttt atctgaagga agtgaacatc agcatgtatt
tggttaatgg ctccgttttc agcattgcaa ataacaatct cagctactgg gatgcccccc tgggaagttc
ttatatgtgc aacaaagagc agactgtttc agtgtctgga gcatttcaga taaatacctt tgatctaagg
gttcagcctt tcaatgtgac acaaggaaag tattctacag cccaagagtg ttcgctggat gatgacacca
ttctaataccc aattatagtt ggtgctggtc ttccaggctt gattatcggt atagtgattg cttacgtaat
tggcagaaga aaaagttatg ctggatatca gactctgtaa cactaatcaa tacgtgatct ctgttacaaa
agaaaaaagc aagtacaagt tccaacatgc aatactggtc aacttaaggt atatttagtt gcagtcacgc
tctttagaat ggggtggtatg ggggatttca aacttaaaca aaaaactatc aactacaaat tagttgcctg
actttggttt ttccaaccaa ggaattttaa actgttattt ttacagcaaa agatgtgcaa aatcactgga
ttataagttc tattttactg tcttgaatta gtatttcagt gttttcattt tagacattca gactaaaaat
acaccgttta gaaaaaacia tttttgaaaa agagattttt tttccctgca ggtagttagg ttgaacaaca
tgttctaccg tggatttgta cttgctcctt ttgctctttt tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg
tgtgattttt gtttgcagggt taacttagct actttggcat tgctgcatat ttgaccttg agagatataa
tagtagattt gaacaggggc tggattatt atgttcttag caataaatgc ttttctaag ccttttgaat
acatttgat ttatgtggct gtaatgacaa aagatacaaa agcttttttaa aatttagagt aggtattaat
cttattgttt aatctttttt ttaaaaaaac tggatatttc aatcttttaa attgcaatat ataagactat
tccaactggg catttcaatc catttttttag gtgctttaga gataattgct tgccagtgcc aattgagggc
attagtactt tgtgctcata aattggcctc tgtatgcagt actaaaatta atgcagattt ctctttagcc
ttccaacatt tcttgttgat agtgatgtat tttattattt tctttttctt aagaaatgcc agtgtgtcct
agaacctaga taacgaagtg cacttacact tataaaataa cttgcatcta ggctgggcgt ggcggctcac

```

```

gcctgtaatc ccagcacttt gggaggccga agtgggtgga tcacttgagg ccaggagttt gagaccagcc
tgccaacat ggtgaaaccc catctctatc agaaatacaa aaaattagct gggcatggtg gtgggcgcct
gtaatcccag ttactcggga ggctgaggca ggagaatcac ttgaaccgga gaggcagagg ttgcggtgag
ccaagagcgc accattgcac tccagccttg ggcgacaaaa acgaaactcc atcttcaaaa caaaacaaaa
caaaacaaac aaacaaacaa aacttgcac ttaaccacaaa gtcttggttt tatcttaatc cattaaggt
tggctctgtt tccagcttgc attgattgct acaacatcac taatttggct ttcacattta aatggttctg
tgctaataca aactttcgtt gttattatc gttatggtag aatcattttt aattcacgtg ctttgtgttc
agtgttgtgg tctgagagat gtaccaattg tcaaattacc gtgtaccacc taatgtttat aggagaaagc
aaaatacatc agcttggtag ttaacacatc aaatatcttct tgctgcttct aggagaactt ttttgggtgtg
tggttggaatg gctgagcaaa tattaaaatt gttaatatgc agccatatat ggaagggttc tgtggggttg
ttttttcgtg tttttttttt ttgtgggtggg attatgtgcc tccattcac tagaaaatga gaaaattgtc
tgggttccaa aatattgaca ttgaatggat caatacacac acacagacat atatatatat atatgcacac
atatataggc agttgcatgc ctagcatggg tattttataa ccatataact gagttatatt ggaattataa
atattttccg tcaactaaat ttgttctttg tttagcctga aaacctttat ggctcaagat cagattcctg
actaaccctt ctcttagagc tacagcgagc tgcattacca gcttaaaaca cttcttaggg attaaatata
gatgtaattt ttcaaaatcg tttttaattt aaactgtgtt ttagtgtaaa attgttaacc ttgtaagatg
gataatgtgt ataagaatgt aggccttaac tatttcacat gagtcaaaac aaagcagctt taaaaaata
attggaagca caatgcatgg cactgactga atgctgttaa tatttctaaa agtttctaca ttcagattat
atgcctgatt catagtataa tacctctaata aaacactgtt ttatagaaaa cctgacttca gtgaatat
ttgtatttta catgggccag tttatatact gctatttaca ctattatttc ctatagctac atgttctttg
taccttttgt agttttatct gtattactag attcatacct tgatggtaac gctctatctg gttttgggtg
tttttcatgt ttttagcatt gtataaagaa actggtccat gtaaataact tccatgtttt ttcttcaaat
gtttaaacca ctagtgtgat tatggtatct ttagatatct gcctgtctgt ttgctcaaaa ttgcttctaa
aacaataaag attctt

```

GenBank Accession No.: AAS67876.1, human LAMP-2C, which provides the amino acid sequence (SEQ ID NO: 25):

```

MVCFRLEFPVPGSGLVLVCLVLGAVRSYALELNLTDSENATCLYAKWQMNFTVRYETTNKTYKTVTISDHGTVTYNG
SICGDDQNGPKIAVQFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFPDAEDKGILTVDELLAIRIPLNDLFR
CNSLSTLEKNDVVQHYWDVLVQAFVQNGTVSTNEFLCDKDKTSTVAPTIHTTVPSPTTTPKEKPEAGTYSVNG
NDTCLLATMGLQLNITQDKVASVININPNTTHSTGSCRSHALLRLNSSTIKYLDVFVAVKNENRFYLKEVNISMY
LVNGSVFSIANNLSYWDAPLGSSYMCNKEQTVSVSGAFQINTFDLRVQPFNVTQGKYSTAECSADSDLNFLIPV
AVGVALGFLIIVVFISYMIGRRKSRTGYQSV

```

GenBank Accession No.: AY561849.1, human LAMP-2C mRNA, complete cds, which provides the nucleic acid sequence (SEQ ID NO: 26):

```

atggtgtgct tccgcctctt cccggttccg ggctcagggc tcgttctggt ctgcctagtc ctgggagctg
tgcggtctta tgcattggaa cttaatttga cagattcaga aaatgccact tgcctttatg caaaatggca
gatgaatttc acagtacgct atgaaactac aaataaaact tataaaactg taaccatttc agaccatggc
actgtgacat ataatggaag catttgtggg gatgatcaga atggtcccaa aatagcagtg cagttcggac
ctggcttttc ctggattgcg aattttacca aggcagcatc tacttattca attgacagcg tctcattttc
ctacaacact ggtgataaca caacatttcc tgatgctgaa gataaaggaa ttcttactgt tgatgaactt
ttggccatca gaattccatt gaatgacctt ttagatgca atagtttatc aactttggaa aagaatgatg
ttgtccaaca ctactgggat gttcttgtac aagcttttgt ccaaaatggc acagtgagca caaatgagtt
cctgtgtgat aaagacaaaa cttcaacagt ggcacccacc atacacacca ctgtgccatc tcctactaca
acacctactc caaaggaaaa accagaagct ggaacctatt cagttaataa tggcaatgat acttgtctgc
tggtaccat ggggctgcag ctgaacatca ctcaggataa gggtgcttca gttattaaca tcaaccccaa
tacaactcac tccacaggca gctgccgttc tcacactgct ctacttagac tcaatagcag caccattaag
tatctagact ttgtctttgc tgtgaaaaat gaaaaccgat tttatctgaa ggaagtgaac atcagcatgt
atttggttaa tggctccgtt ttcagcattg caaataacaa tctcagctac tgggatgcc ccctgggaag
ttcttatatg tgcaacaaag agcagactgt ttcagtgtct ggagcatttc agataaatac ctttgatcta
agggttcagc ctttcaatgt gacacaagga aagtattcta cagctgaaga atgttctgct gactctgacc
tcaactttct tattcctgtt gcagtgggtg tggccttggg cttccttata attgttgtct ttatctctta
tatgattgga agaaggaaaa gtcgtactgg ttatcagtct gtgtaa

```

[0096] In another aspect, the method of treating lysosomal transmembrane protein disease or disorder in a subject includes contacting cells expressing a protein associated with the particular disease or disorder (see Table 1) from the subject with a vector encoding a gene editing system that when transfected into the cells removes a mutation (*e.g.*, a trinucleotide repeat expansion mutation) of the endogenous protein, thereby treating the lysosomal transmembrane protein disease or disorder. In various embodiments, the gene editing system is selected from the group consisting of CRISPR/Cas, zinc finger nucleases, and transcription activator-like effector nucleases. The step of contacting may be performed *ex vivo* by first obtaining a sample of cells from the subject, transfecting the gene editing system into the sample of cells, and thereafter transplanting the transfected cells into the subject, thereby treating the lysosomal transmembrane protein disease or disorder. The sample of cells may be any cells expressing the protein associated with the lysosomal transmembrane protein disease or disorder, such as, for example, blood cells or HSPCs of the subject.

[0097] In another aspect, the the present invention provides a method of treating or ameliorating a lysosomal protein disease or disorder in a subject. The method includes transplanting a population of HSPCs into the subject, wherein the HSPCs have been genetically modified by introduction of a transgene encoding a corresponding functional human lysosomal transmembrane protein, thereby treating the lysosomal transmembrane protein disease or disorder. Thus, when the lysosomal transmembrane protein disease or disorder is cystinosis, the functional human lysosomal transmembrane gene is CTNS; the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the functional human lysosomal transmembrane gene is SLC17A5; the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the functional human lysosomal transmembrane gene is LMBRD1; the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is MFSD8; the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is CLN3; the lysosomal transmembrane protein disease or disorder is malignant infantile osteopetrosis, the functional human lysosomal transmembrane gene is CLCN7 or OSTM1; the lysosomal transmembrane protein disease or disorder is mucopolidosis IV, the functional human lysosomal transmembrane gene is MCOLN1; the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the functional human lysosomal transmembrane gene is HGSNAT; the lysosomal transmembrane protein

disease or disorder is Neiman-Pick Type C, the functional human lysosomal transmembrane gene is NPC1; and the lysosomal transmembrane protein disease or disorder is Danon disease, the functional human lysosomal transmembrane gene is LAMP2. In various embodiments, the HSPCs are isolated from the subject, such as from the bone marrow of the subject.

[0098] While the present invention has been demonstrated with regard to cystinosis and Danon disease, it should be understood that the methods are applicable to any of the diseases or disorders set forth in Table 1. Thus, this strategy turns HSPCs into intelligent and widespread delivery vehicles to obtain stable and sustained cross-correction after their differentiation into monocytes that enter the circulation and subsequently invade the peripheral tissues where they transform into tissue resident macrophages. These macrophages, through a variety of mechanisms including, but not limited to, the formation of tunneling nanotubes, vesicular release, and direct cell-cell adhesion, transfer their lysosomes, which carry the respective protein to diseased peripheral cells. As such, this work demonstrates the development of a HSPC gene therapy strategy for treating lysosomal transmembrane protein diseases or disorders.

[0099] The following examples are intended to illustrate but not limit the invention.

EXAMPLE 1

Preclinical Model of Cystinosis for Testing Therapeutic Approaches

[0100] Stem cell therapeutic approaches have been tested on the mouse model of cystinosis, the *Ctns*^{-/-} mice. This murine model was engineered to produce defective cystinosin, and is thus unable to properly transport cystine out of the lysosomes. The defect results in accumulation of cystine and formation of cystine crystals, pathognomonic of cystinosis. Cystine accumulation is present from birth and increases with age. The original *Ctns*^{-/-} mice have been backcrossed to generate a pure strain of C57BL/6 *Ctns*^{-/-} mice, which develop renal dysfunction from 6-months of age, as observed biochemically (elevated serum urea and creatinine) and histologically, and these mice are in end stage renal failure by 18 months. Renal Fanconi syndrome also starts around 6 months old (polyuria, phosphaturia and proteinuria), proximal tubular cells appear de-differentiated, and exhibit the typical “swan-neck” deformity found in mice and humans with cystinosis resulting in atubular glomeruli. Finally, heavy infiltration of inflammatory cells can be observed in the kidney of the *Ctns*^{-/-}

mice. *Ctns*^{-/-} mice also develop ocular defects with corneal cystine crystal depositions and thyroid dysfunction similar to those observed in affected patients.

EXAMPLE 2

Impact of BMC, HSC and MSC Transplantation on Cystinosis

[0101] To determine the appropriate cell population for transplantation in the context of cystinosis, syngeneic bone marrow cell (BMC), *Sca1*⁺ hematopoietic stem cell (HSC) and mesenchymal stem cell (MSC) transplantations were performed in 2 month-old irradiated *Ctns*^{-/-} mice. The cells were isolated from either green fluorescent protein (GFP)-transgenic wild-type (WT) mice or from *Ctns*^{-/-} mice as controls. Analyses of disease parameters were performed 4 months post-transplantation. MSCs had only a short-term limited beneficial impact on the disease. In contrast, tissue cystine content was significantly reduced in all organs tested in the WT BMC and HSC-treated mice (from 57% to 94% decrease depending on tissues). Abundant GFP⁺ bone marrow-derived cells were present in all organs and kidney function was improved. This was the first proof of concept that HSCs could rescue cystinosis even if cystinosis is a transmembrane lysosomal protein as opposed to a secreted enzyme.

EXAMPLE 3

Long-term Effect of HSC Transplantation in *Ctns*^{-/-} mice

[0102] It was then determined if this treatment was stable for the life of the mice and could result in multi-organ preservation.

[0103] *Kidney analysis:* Transplantation of WT HSCs was able to provide long-term protection of the kidney function and structure and prevented the progression of the renal disease up to 15 months post-transplantation (last time point tested; Figure 1). However, effective therapy depends on achieving a relatively high level of donor-derived blood cell engraftment of *Ctns*-expressing cells (>50%), which is directly linked to the quantity of *Ctns*-expressing cells found within the kidney. In contrast, kidney preservation was not dependent on the age of the mice at the time of transplant. Indeed, up to 10-month-old mice could exhibit normal kidney function after stem cell treatment, suggesting that if tissue injury is not consolidated, kidney could be rescued. It was also shown that cystine content was significantly decreased in all tissues (from 54% in the kidney to 96.5% in the liver) proving that the treatment, consisting in a one-time HSC transplantation, led to long-term and stably low levels of tissue cystine for the life span of the mice. Moreover, few to no cystine crystals

were observed in all kidneys from treated mice whereas abundant cystine crystals were consistently observed in kidneys from non-treated *Ctns*^{-/-} mice.

[0104] *Eye analysis:* GFP⁺ WT HSC transplantation led to the long-term preservation of the eyes in *Ctns*^{-/-} mice. Abundant GFP⁺ bone marrow-derived cells were detected within the cornea but also in the sclera, ciliary body, retina, choroid, and lens in the treated mice. To quantify cystine crystals within the cornea, *in vivo* confocal microscopy (IVCM) in live mice was performed. Effective therapy was dependent dependent on the level of donor-derived blood cell engraftment as previously demonstrated for the kidney. While *Ctns*^{-/-} mice with low level of engraftment (<50%; LOW; n=5) presented a partial reduction of crystal counts, the mice with high engraftment levels (>50%; HIGH; n=5) exhibited almost a complete resolution of crystals from the epithelial layer to the middle stroma (100% to 72% clearance, respectively; Figure 2). One-year post-transplantation, HSC-treated *Ctns*^{-/-} mice exhibited normal corneal thickness and structure and normal intraocular pressure. This work was the first demonstration that transplanted HSCs could rescue corneal defects and brings new perspectives for ocular regenerative medicine.

[0105] *Thyroid analysis:* Since the thyroid gland is also affected in cystinosis, thyroid function and structure from *Ctns*^{-/-} mice and HSC-transplanted mice were analyzed. Sustained thyroid stimulating hormone (TSH) activation combined with morphological evidence for increased thyroglobulin synthesis was shown in *Ctns*^{-/-} mice. Follicular changes included thyrocyte hypertrophy, hyperplasia, colloid exhaustion and vascular proliferation. In contrast, *Ctns*^{-/-} mice treated by HSC transplantation presented virtually normal histology and normalization of cystine and TSH values (Figure 3).

[0106] *Gastro-intestinal tract analysis:* Gastrointestinal mucosal biopsies can be used to measure gene-modified stem cell tissue engraftment and their impact on cystine and cystine crystal levels in subjects enrolled in the HSC gene therapy clinical trial for cystinosis. It has been previously described that an histologic technique for evaluating tissue cystine crystal levels on intestinal mucosal biopsies. It was shown that cystine crystal counts could be correlated with renal function and could help evaluating the response to cysteamine treatment. Thus, a rectal biopsy is planned before and every 6 months after gene-corrected HSC transplantation in the subjects with cystinosis. Up to 9 biopsies can be obtained at a time so it is possible to measure Vector Copy number (VCN), CTNS expression, cystine content and cystine crystals in this tissue at each time point. To establish if this tissue is representative of

the efficacy of the treatment, the impact of GFP⁺ WT HSC transplantation on the gastrointestinal tract in Ctns^{-/-} mice was studied. Six months posttransplant, abundant GFP⁺ HSC-derived cells were observed in both intestine and colon tissues and cystine content was significantly decreased in treated mice compared to controls in these compartments (Figure 4).

[0107] *Skin analysis:* *In vivo* confocal microscopy is used on the skin as a noninvasive imaging technology for the visualization and quantification of tissue cystine crystals before and after HSC transplantation in the subjects with cystinosis enrolled in the clinical trial. Chiaverini et al. (Journal of the American Academy of Dermatology 68, e111 (2013)) showed that this technology was able to detect dermal cystine deposition in patients with cystinosis. For this purpose, a reflectance confocal imager (Caliber VIVASCOPE® 3000) adapted for skin imaging was used to test patients with cystinosis. It was also shown in the HSC-transplanted Ctns^{-/-} mice that abundant GFP⁺ bone marrow-derived cells engrafted within the skin leading to significant cystine decrease in this tissue (79 ± 0.87 in HSC-treated Ctns^{-/-} vs 193 ± 78 in controls, $p < 0.05$).

EXAMPLE 4

Myeloablative Conditioning Regimen: Efficacy and Toxicity in Ctns^{-/-} mice

[0108] Ctns^{-/-} mice were exposed to myeloablative drugs currently used in clinic for HSC transplantation, Busulfan (Bu) and Cyclophosphamide (Cy) to test if drug-mediated myeloablation allow efficient engraftment of Ctns-expressing HSC in the preclinical model, decreased tissue cystine and to determine if any unexpected toxicity occurs because of cystinosis. Drugs were injected intraperitoneally (IP) in Ctns^{-/-} mice and WT mice as controls. The mice were analyzed at 4 months post-transplant, demonstrating that: i) Ctns^{-/-} mice did not present any toxicity to Bu or Cy compared to WT controls; ii) Renal function was similar to non-treated age-matched WT controls; iii) Myeloablation was successful in both cases and reached a donor cell engraftment measured in the peripheral blood of $94.2 \pm 1.6\%$ for Bu/Cy and $94.0 \pm 0.8\%$ for Bu alone; and iv) Treated Ctns^{-/-} mice had a significant decrease of cystine in all tissues tested compared to non-treated. Thus, Bu and Cy are not toxic in the mouse model for cystinosis and drug-mediated myeloablation and HSC transplantation in Ctns^{-/-} mice led to significant decrease of cystine in all tissues.

[0109] The dosing for myeloablation can be done using busulfan alone without cyclophosphamide. Cyclophosphamide does not ablate the hematopoietic stem cells (i.e., does

not make engraftment space), and is immune suppressive and anti-leukemic. Since the HSC transplant is autologous, and not for leukemia, cyclophosphamide is not needed, as it adds unnecessary toxicity to the conditioning regimen. Moreover, it is unusual for severe nephrotoxicity to arise directly due to commonly used-conditioning regimen agents such as busulfan. Note that Dr. Donald Kohn's sickle cell trial (ClinicalTrials.gov Identifier: NCT02247843) is only using busulfan, and the sickle cell and thalassemia trials of bluebird bio, Inc. (ClinicalTrials.gov Identifier: NCT02151526) are also using busulfan without cyclophosphamide.

EXAMPLE 5

Mechanism of Therapeutic Action

[0110] The extent of efficacy of HSCs to rescue cystinosis was surprising especially considering that the ability of HSC transplantation to rescue non-hematopoietic tissue remains contentious and that cystinosis is a transmembrane lysosomal protein. To elucidate the mechanism of HSC-mediated tissue repair, a novel mouse model was developed, in which *Ctns*^{-/-} mice back-crossed on a DsRed background so as to ubiquitously express the DsRed reporter gene (Harrison *et al.*, Mol Ther 21, 433 (2013)). When transplanted with GFP-expressing HSCs derived from GFP-transgenic mice, this generated a bifluorescent mouse model that not only allowed us to track the fate of the transplanted HSCs in an *in vivo* setting, but also enabled sensitive identification and unequivocal discrimination of events such as fusion, differentiation, and transdifferentiation.

[0111] Using this model, it was first shown that HSCs differentiated into macrophages within tissues (Naphade *et al.*, Stem Cells 33, 301 (2015)). *In vitro* co-culture experiments were then performed using WT GFP-macrophages and DsRed-*Ctns*^{-/-} fibroblasts. When WT macrophages were co-cultured with *Ctns*^{-/-} fibroblasts, cystine levels decreased by ~75% in FACS-sorted fibroblasts (Figure 5A). In contrast, when the two populations were physically separated using a transwell porous to microvesicles, cystine levels decreased only by ~20% (Figure 5B). These findings showed that cross-correction occurs even if cystinosis is a lysosomal transmembrane protein and that direct cell:cell contact is the main pathway for cross-correction. Using confocal microscopy (Figure 5C), it was observed that macrophages extended long membrane protrusions called tunneling nanotubes (TNTs) (~40 μm) that established contact with the fibroblasts. To determine whether TNTs could mediate the physical transfer of cystinosis-bearing vesicles, DsRed-*Ctns*^{-/-} fibroblasts were co-cultured

with macrophages stably transduced with a lentivirus vector expressing cystinosin-GFP fusion protein (CTNS-GFP-macrophages). Live confocal microscopy revealed that vesicles containing cystinosin-GFP could migrate along TNTs towards DsRed-Ctns^{-/-} fibroblasts (Figure 5D). LysoTracker staining identified these vesicles as lysosomes (Naphade *et al.*, Stem Cells 33, 301 (2015)).

[0112] Very little is known about TNTs *in vivo*. It was thus examined whether intercellular vesicular exchange involving nanotubes could be detected *in vivo*, so as to account for the long-term kidney preservation in Ctns^{-/-} mice. The initial focus was on the kidney not only because of the early occurrence of cystinosis in proximal tubular cells (PTCs) but also because of their physical isolation by the dense tubular basement lamina (TBL). In the two-color grafted mice, GFP⁺ bone marrow-derived cells were observed surrounding but never within the proximal tubules and numerous tubular extensions emanated from the HSC-derived macrophages and crossed the TBL (Figures 6A-a1 to 6A-a3). GFP-containing structures were observed within PTCs, indicating physical transfer of cytoplasm from the macrophages into the epithelia (Figure 6A-a3). To test this hypothesis, Ctns^{-/-} mice were transplanted with DsRed-Ctns^{-/-} HSPCs stably expressing cystinosin-GFP fusion protein (Figure 4C) or with DsRed-Ctns^{-/-} HSPCs (Figure 4B). Many cystinosin-GFP-vesicles were observed in PTCs (Figure 4C) (Naphade *et al.*, Stem Cells 33, 301 (2015)). This is the first evidence of direct transfer of proteins from interstitial macrophages to epithelial cells via TNTs penetrating the TBL, so as to correct a genetic defect leading to PTC degeneration. Similar data were obtained for the mechanism of HSC-mediated therapeutic action for the ocular defects (Rocca *et al.*, Investigative ophthalmology & visual science 56, 7214 (2015)) and for the thyroid rescue (Chevonnay *et al.*, Endocrinology In press, (2016)) in the Ctns^{-/-} mice. These findings on HSC-mediated tissue repair bring new perspectives to regenerative medicine, as they should be applicable to other multi-compartment disorders involving deficient intracellular organelles.

EXAMPLE 6

Clinical study for Hematopoietic Stem Cell Transplantation

[0113] The work described above represents the first proof-of-concept for using HSC transplantation as a therapy for cystinosis. To minimize the risks of Graft-versus-host (GVHD), subjects are required to have a sibling bone marrow donor who is HLA-matched on 10 of 10 alleles. This study was designed to include six subjects who are either adults ages 18 years and older with significant signs of disease progression or adolescents ages 13-17 years

who do not tolerate cysteamine. However, given the rarity of the disease and strict donor requirements, the candidates so far were not complete matches with their sibling. In addition, the risk-benefit ratio for allogeneic HSC transplantation may not be ideal for young patients where the introduction of regular use of the drug cysteamine has permitted patients to live to adulthood, albeit with significant medical problems (Cherqui, *Kidney Int* 81, 127 (2012)). Indeed, there are significant risks of morbidity and mortality associated with allogeneic transplantation. GVHD is a major complication; in recent studies, acute GVHD grade II-IV occurred in 20% to 32% of patients and chronic GVHD in 16% to 59%, both significantly impacting survival of the recipients (Cutler *et al.*, *Blood* 109, 3108 (2007); Geyer *et al.*, *Br J Haematol* 155, 218 (2011); and Schleuning *et al.*, *Bone Marrow Transplant* 43, 717 (2009)). Thus, a preferred candidate therapy would utilize the patient's own stem cells for an autologous HSC transplantation, thereby mitigating the risks of graft rejection and GVHD.

EXAMPLE 7

Viral Vector Selection

[0114] Given the risks associated with allogeneic HSC transplantation and considering the preclinical data for HSC gene therapy, transplantation of autologous HSC modified to express function cystinosis represents a safer approach.

[0115] With regard to gene therapy, vectors derived from lentiviruses have supplanted γ -retroviral vectors due to their superior gene transfer efficiency and improved biosafety profile (Case *et al.*, *Proc Natl Acad Sci USA* 96, 2988 (1999); Miyoshi, *et al.* *Science* 283, 682 (1999); Naldini *et al.*, *Science* 272, 263 (1996); and Varma *et al.*, *Nature* 389, 239 (1997)). Specifically:

1. All cases of leukemogenic complications observed to date in clinical trials or animal models of gene therapy involved the use of γ -retroviral vectors such as Moloney Leukemia Virus (MLV) retrovirus with long terminal repeats (LTR) containing strong enhancer/promoters that can trigger distant enhancer activation (Hacein-Bey-Abina *et al.*, *J Clin Invest* 118, 3132 (2008); Li *et al.*, *Science* 296, 497 (2002)).
2. In contrast, the third-generation of lentivirus vectors, Self-inactivated (SIN)-lentivirus vectors (LV), with the deletions in their LTR, contain only one internal enhancer/promoter, which reduces the incidence of interactions with nearby cellular genes and thus decreases the risk of oncogenic integration (Modlich *et al.*, *Blood*

108, 2545 (2006); Montini *et al.*, J Clin Invest 119, 964 (2009)). Moreover, in contrast to the MLV, lentiviruses are not associated with oncogenesis. Importantly, leukemia is not a recognized side effect of HIV patients even though memory T cells are known to carry integrated virus for years.

3. SIN-LTR are also designed to prevent the possibility of developing replication competent lentivirus (RCL) during production of the viral supernatants. Indeed, transient transfection systems with three packaging plasmids are usually employed for vector production - gag, pol, and rev (Dull *et al.*, J Virol 72, 8463 (1998)). A fourth plasmid containing the gene coding for the envelope and vesicular stomatitis virus glycoprotein (VSV-G) is frequently used as the choice of envelope. So far RCL has never been reported with this commonly used viral production system in patients after infusion of the vector transduced cell products (Sastry *et al.*, Mol Ther 8, 830 (2003)).
4. LV efficiently transduce HSCs and do not alter their repopulation properties (Montini *et al.*, J Clin Invest 119, 964 (2009); Gonzalez-Murillo *et al.*, Blood 112, 3138 (2008)).
5. Clinical trials using SIN-LV to transduce human HSCs are being undertaken in the U.S. and Europe for several conditions including HIV-1, β -thalassemia, immune deficiencies and cancers (DiGiusto *et al.*, Viruses 5, 2898 (2013); Drakopoulou *et al.*, Current molecular medicine 13, 1314 (2013); Porter *et al.*, N Engl J Med 365, 725 (2011); and Zhang *et al.*, Gene Ther 20, 963 (2013)). For immune deficiency disorders, 35 patients have been transplanted with SIN-LV-modified HSCs so far (Bigger *et al.*, Discovery medicine 17, 207 (2014)). A clinical trial using a SIN-LV to correct *ex vivo* HSCs in patients with X-adrenoleukodystrophy showed that cerebral demyelination was arrested in the two enrolled patients without further progression over 3 years of follow-up; and there was no evidence of clonal dominance (Cartier *et al.*, Methods Enzymol 507, 187 (2012); Cartier *et al.*, Science 326, 818 (2009)). Recently, a clinical trial for Wiskott-Aldrich was reported in three patients 32 months post-transplantation. Stable and long-term engraftment of the gene-modified HSCs (25-50%) resulted in improved platelet counts, protection from bleeding and infections, and resolution of eczema (Aiuti *et al.*, Science 341, 1233151 (2013)). Another clinical success was recently reported in three

presymptomatic patients with Metachromatic Leukodystrophy. Donor-derived blood cell engraftment of transduced cells achieved 45 to 80% and up to 24 months later the protein activity was reconstituted to above normal values in cerebrospinal fluid associated with a clear therapeutic benefit (Biffi *et al.*, Science 341, 1233158 (2013)).

[0116] pCCL-CTNS lentiviral vector - a third-generation SIN-lentiviral vector in which human CTNS cDNA has been subcloned, pCCL-CTNS (Figure 7), was prepared for use. The vector backbone pCCL-EFS-X-WPRE, described by Zufferey *et al.* (J Virol 72, 9873 (1998)), was provided by Dr. Donald Kohn (UCLA). A central polypurine tract (cPPT) fragment that increases the nuclear import of viral DNA was added to the CCL vector backbone (Demaision *et al.*, Hum Gene Ther 13, 803 (2002)). A Woodchuck hepatitis virus Posttranslational Regulatory Element (WPRE) is present to boost titer and gene expression. However, its open-reading frame was eliminated (Zanta-Boussif *et al.*, Gene Ther 16, 605 (2009)) because it overlapped with the woodchuck hepatitis virus X protein, a transcriptional activator involved in the development of liver tumors (Kingsman *et al.*, Gene Ther 12, 3 (2005)). The transgene expression is driven by the ubiquitously expressed short intron-less human Elongation Factor 1 alpha promoter (EFS, 242 bp) (Wakabayashi-Ito, S. Nagata, J Biol Chem 269, 29831 (1994)). The EFS promoter, which lacks the intron and enhancers of the larger element used in many expression plasmids, has been shown to direct high level transcription of reporter genes in murine HSCs and to have significantly reduced trans-activation potential compared to γ -retroviral LTR (Zychlinski *et al.*, Mol Ther, (2008)).

[0117] Vectors with this backbone are used in clinical trials conducted by Dr. Kohn: i) Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells after Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID) (BB IND 15440; NCT01852071); ii) Autologous Bone Marrow Stem Cells (CD34+) Cultured W/ Cytokines; Transduced W/ Self-inactivating (SIN) Lentiviral Vector Expressing Human β -globin (LENTI/BetaAS3-FB); following Busulfan (BB IND 16028; NCT02247843).

EXAMPLE 8**Preclinical studies for transplantation of pCCL-CTN-transduced HSCs**

[0118] Scal^+ HSCs isolated from $\text{Ctns}^{-/-}$ mice were transduced ex vivo with pCCL-CTNS using our optimized protocol for mHSCs and transplanted into 1 to 4 month old $\text{Ctns}^{-/-}$ mice. Cystine content in brain, eye, heart, kidney, liver, muscle, and spleen were analyzed after 4 (group 1; n=8) and 8 (group 2; n=12) months post-transplantation. As controls, age matched non-treated $\text{Ctns}^{-/-}$ mice (n=7 and n=12) were used or $\text{Ctns}^{-/-}$ mice transplanted with WT HSCs (n=4 and n=4). Decreases in cystine content were statistically significant in all the tissues tested in mice treated with pCCL-CTNS-transduced HSCs compared to $\text{Ctns}^{-/-}$ controls (Figure 8A). The impact of $\text{Ctns}^{-/-}$ HSCs transduced with control vector, pCCL-GFP, was also tested on tissue cystine levels to exclude the possibility that the presence of any transgene results in cystine decreases. No decrease in any tissue was observed in mice transplanted with pCCL-GFP- $\text{Ctns}^{-/-}$ HSCs compared to non-treated $\text{Ctns}^{-/-}$ mice (Harrison *et al.*, Mol Ther 21, 433 (2013)).

[0119] Renal glomerular and tubular function was assessed by measuring creatinine, urea, and phosphate levels in the serum, and creatinine clearance in 24-hour urine in males at 8 months post-transplant and compared to age-matched WT males (n=6). All the parameters were increased and the creatinine clearance decreased in non-treated $\text{Ctns}^{-/-}$ mice compared to WT mice. In the pCCL-CTNS-treated $\text{Ctns}^{-/-}$ mice, serum creatinine, urine phosphate and urine volume were significantly decreased compared to controls, showing a beneficial effect of the genetically modified HSC on kidney function in the $\text{Ctns}^{-/-}$ mice. Significant reduction of cystine crystals present in kidney sections was demonstrated in the treated $\text{Ctns}^{-/-}$ mice compared controls (Figures 8B and 8C). Note that we showed that cystine content in female kidneys was five times more elevated than in male kidney in $\text{Ctns}^{-/-}$ mice, thus studies on kidney have to be performed on males and females separately (Harrison *et al.*, Mol Ther 21, 433 (2013)).

[0120] Quantitative PCR (qPCR) was performed on genomic DNA isolated from blood collected from pCCL-CTNS-transplanted $\text{Ctns}^{-/-}$ mice using lentiviral-specific primers to determine the Vector Copy Numbers per cell (VCN). Average VCN was 1.573 ± 1.868 , which fell in the targeted range of VCN 1-3. To determine if lentivirus levels could be predicted in tissues, linear regression analyses was performed between pCCL levels in the different tissues as a function of blood VCN levels. Direct correlation between the levels of lentivirus present in

the blood and the levels present in tissues was demonstrated (Harrison *et al.*, Mol Ther 21, 433 (2013)), which is useful to follow the future subjects enrolled in the clinical trial.

EXAMPLE 9

Pre-clinical Pharmacology and Toxicology

[0121] The pharmacology/toxicology studies for HSCs ex-vivo gene-modified with pCCL-CTNS are performed using a batch of pCCL-CTNS lentiviral vector preparation produced under comparable-Good Manufacturing Practice (GMPc) obtained from the Indiana University Vector Production Facility (IUVPF), directed by Dr. Kenneth Cornetta. The targeted VCN range that was proposed to the FDA for safety is included between 1 and 3.

[0122] The In Vitro Immortalization (IVIM) assays, a genotoxicity test, was performed by the Translational Trials Development and Support Laboratory at the Cincinnati Children's Hospital Medical Center. This assay consists in mass culture expansion of transduced murine Lin- BMC for 2 weeks followed by culture in 96-well plates at a density of 100 or 10 cells/well for up to 7 weeks (Arumugam *et al.*, Mol Ther 17, 1929 (2009); Modlich *et al.*, Mol Ther 17, 1919 (2009)). The positive wells are counted and the frequency of replating cells calculated and compared to a negative (mock transduced) and positive control (MLV vector). The IVIM assays were performed in triplicates using GMPc pCCL-CTNS preparation with a VCN ranged between 1-3. No immortalized clone was produced with the construct, thus demonstrating an excellent safety profile.

[0123] *In vivo* pharmacology/toxicology studies are currently being conducted with the analogous cell therapy product consisting in Sca1⁺ mHSCs in the Ctns^{-/-} mice involving serial transplantation. 15-20 Ctns^{-/-} mice (10 males and 10 females) were transplanted with pCCL-CTNS-transduced Ctns^{-/-} mHSCs (with a VCN 1-3) and 20 with mock-transduced Ctns^{-/-} mHSCs as Primary Recipients. Subsequently, bone marrow cells derived from each of these mice are transplanted into Secondary Ctns^{-/-} mice. The Primary and Secondary mice have to be fully analyzed 6 months post-transplantation by comprehensive molecular, clinical and histological analyses. So far, we have 32 Primary Recipients that reached the 6-month time points: 11 Ctns^{-/-} mice transplanted with pCCL-CTNS-transduced Ctns^{-/-} mHSCs (with VCN included in 1-3) and 21 mock-treated mice, and 18 Secondary mice. No adverse event has been detected so far, the data show efficacy of the product as the weight of the mice treated with pCCL-CTNS-HSCs is higher and the cystine content in the tissues tested is significantly lower

than the mock-treated controls (Figures 9A-9B). Thus, we have to reach the 6 month-time point for up to 9 additional Ctns^{-/-} Primary Recipients treated with pCCL-CTNS-transduced HSCs and for 15 Secondary Recipients.

EXAMPLE 10

Manufacturing: Process development

[0124] Using the GMPc pCCL-CTNS preparation, a protocol was optimized to transduce human CD34⁺ HSCs from healthy donors to obtain a VCN included between 1 and 3. This protocol involved a one-hit vector transduction at a MOI 20 for 20 hours. Colony Forming Unit (CFU) assays were then performed using human CD34⁺ peripheral blood stem cell (PBSC) isolated from five healthy donors and four cystinotic patients and neither showed aberrant proliferation or differentiation potential with pCCL-CTNS LV compared to mock-transduced controls. Moreover, Vector Integration Site (VIS) analyses in the patient's cells showed no enrichment of the integration sites near proto-oncogene 5' ends. However, while this protocol led to an average VCN of 2 in healthy CD34⁺ cells, the average VCN in cystinosis patients was 0.96. Therefore, the protocol was further optimized with the cystinosis patients' cells to achieve a higher level of transduction as we have demonstrated that a higher level of cells expressing CTNS leads to a better therapeutic response (Yeagy *et al.*, Kidney Int 79, 1198 (2011); Rocca *et al.*, Investigative ophthalmology & visual science 56, 7214 (2015); Harrison *et al.*, Mol Ther 21, 433 (2013)). This protocol involves a two-hit vector transduction at a MOI 20 each for 24-hour total and an average VCN of 1.9 with patients' cells was obtained. CFU assays and VIS have now to be repeated with this new protocol.

[0125] For the clinical trial, the transduction protocol is performed according to the GMP facility's standard operating procedures and uses the optimal protocol for cystinosis patients' CD34⁺ cells. Note that prior to enrolling the first patient, optimal conditions for large-scale transductions using the GMP-grade pCCL-CTNS vector preparation and optimal protocol are validated in small scales and Proficiency Runs using human CD34⁺ cells from healthy donors at the GMP facility. The clinical trial will include six patients affected with cystinosis, four adults and two adolescents. This will be a first-in-human clinical trial for an autologous stem cell and gene therapy treatment strategy for cystinosis. If successful, this treatment could be a life-long therapy that may eliminate or reduce renal deterioration and the need for kidney transplantation, as well as, the long-term complications associated with cystinosis. Additionally, the mechanism by which transplantation of pCCL-CTNS-modified CD34⁺ HSCs

provide beneficial and protective effects may be applicable to other inherited multi-organ degenerative disorders.

EXAMPLE 11

HSPC Transplantation for Danon Disease

[0126] The objective of this experiment is to determine whether Danon disease can be rescued by HSPC transplantation and to determine whether lysosomal cross-correction occurs. Using the mouse model described herein, it has been demonstrated that the hearts of Lamp2 KO mice exhibit increased numbers of abnormal mitochondria, and impairments in mitophagy and mitochondrial respiration, which is consistent with prior studies in induced pluripotent stem cell (hiPSC)-derived cardiac myocytes from Danon patients (Cherqui, *Kidney Int* 81, 127 (2012)), confirming similarities between the mouse model and human disease.

[0127] To evaluate the ability of WT HSPCs to rescue Danon disease, two month old lethally irradiated Lamp2 KO mice were transplanted with Sca1⁺ HSPCs isolated from congenic C57BL/6 WT that ubiquitously expressed cytoplasmic eGFP (Tg(ACTB-EGFP)10sb/J from Jackson Laboratory) (WT-HSPCs) using transplantation previously described protocols (Yeagy *et al.*, *Kidney Int* 79, 1198 (2011); Naphade *et al.*, *Stem Cells* 33, 301 (2015); Case *et al.*, *Proc Natl Acad Sci U S A* 96, 2988 (1999)). As negative controls, Lamp2 KO mice were also transplanted with Sca1⁺ HSPCs from Lamp2 KO mice that constitutively expressed eGFP (KO-HSPCs). Skeletal muscle strength was assayed using previously described techniques and demonstrated significantly decreased grip strength in Lamp2 KO mice in comparison to both WT and Lamp2 mice that had received WT HSPCs (Figure 11). LAMP2 protein expression, as assessed by Western blot analyses, was restored to near WT levels in hearts and skeletal muscle of Lamp2 KO mice transplanted with WT HSPCs (Figures 10D-10E).

[0128] To demonstrate that LAMP2 was expressed within cardiac myocytes of recipient Lamp2 KO mice, and not just within donor macrophages residing in those hearts, immunofluorescence studies were performed that demonstrated LAMP2⁺ vesicles in cardiomyocytes (α -actinin: white) located adjacent to donor macrophages (Figures 10A-10C). EM analyses showed decreased vacuoles in Lamp2 KO mice that received WT HSPCs in comparison to Lamp2 KO Mice (Figures 11A and 11B), exhibiting an appearance similar to that of WT mice. Improved autophagic flux following WT HSPC transplant of Lamp2 KO

mice was confirmed by assessing LC3-II/GAPDH levels (Figures 11C-11D). In summary, these studies demonstrate the restoration of physiologic and metabolic function in Lamp2 KO mice treated with WT HSPC transplantation.

[0129] Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

What is claimed is:

1. A method of treating a lysosomal transmembrane protein disease or disorder in a subject comprising:
 - introducing a corresponding functional human lysosomal transmembrane protein into hematopoietic stem and progenitor cells (HSPCs) of the subject; and
 - transplanting the HSPCs into the subject,
 thereby treating the lysosomal transmembrane protein disease or disorder.
2. The method of claim 1, wherein when:
 - (a) the lysosomal transmembrane protein disease or disorder is cystinosis, the corresponding functional human lysosomal transmembrane protein is cystinosin (CTNS);
 - (b) the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the corresponding functional human lysosomal transmembrane protein is sialin (SLC17A5);
 - (c) the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the corresponding functional human lysosomal transmembrane protein is LMBD1;
 - (d) the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the corresponding functional human lysosomal transmembrane protein is CLN7;
 - (e) the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the corresponding functional human lysosomal transmembrane protein is Battenin (CLN3);
 - (f) the lysosomal transmembrane protein disease or disorder is malignant infantile osteopetrosis, the corresponding functional human lysosomal transmembrane protein is ClC-7 or OSTM1;
 - (g) the lysosomal transmembrane protein disease or disorder is mucopolipidosis IV, the corresponding functional human lysosomal transmembrane protein is TRPML-1;
 - (h) the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the corresponding functional human lysosomal transmembrane protein is HGSNAT;

- (i) the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the corresponding functional human lysosomal transmembrane protein is NPC-1; and
 - (j) the lysosomal transmembrane protein disease or disorder is Danon disease, the corresponding functional human lysosomal transmembrane protein is LAMP2.
- 3. The method of claim 1, wherein the step of introducing comprises contacting a vector comprising a polynucleotide encoding functional human lysosomal transmembrane protein and a functional promoter with the HSPCs and allowing expression of the functional human lysosomal transmembrane protein.
- 4. The method of claim 1, wherein the lysosomal transmembrane protein disease or disorder is cystinosis and the functional human lysosomal transmembrane protein is CTNS.
- 5. The method of claim 1, wherein the lysosomal transmembrane protein disease or disorder is Danon disease and the functional human lysosomal transmembrane protein is LAMP2.
- 6. The method of claim 5, wherein the LAMP-2 is an isoform selected from the group consisting of LAMP-2A, LAMP-2B, LAMP-2C.
- 7. The method of claim 1, wherein the subject is a mammal.
- 8. The method of claim 7, wherein the subject is human.
- 9. The method of claim 1, wherein the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector.
- 10. The method of claim 9, wherein the vector is a self-inactivating (SIN)-lentivirus vector.
- 11. The method of claim 4, wherein the vector is a self-inactivating (SIN)-lentivirus vector.
- 12. The method of claim 11, wherein the vector is pCCL-CTNS.

13. The method of claim 5, wherein the vector is a self-inactivating (SIN)-lentivirus vector.
14. The method of claim 13, wherein the vector is pCCL-LAMP2.
15. The method of claim 1, wherein the step of introducing is performed *ex vivo*.
16. The method of claim 1, wherein the HSPCs are isolated from the bone marrow of the subject.
17. A vector comprising a promoter functionally linked to a polynucleotide encoding a functional human lysosomal transmembrane protein selected from the group consisting of CTNS, SLC17A5, LMBRD1, CLN7, CLN3, CLC-7, OSTM1, TRPML1, HGSNAT, NPC1, and LAMP2.
18. The vector of claim 17, wherein the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector.
19. The vector of claim 17, wherein the vector is a self-inactivating (SIN)-lentivirus vector.
20. The vector of claim 19, wherein the vector is pCCL-CTNS.
21. An isolated mammalian host cell containing the expression vector according to any one of claims 17-20.
22. The isolated mammalian host cell of claim 21, wherein the cell is an HSPC.
23. A method of treating or ameliorating a lysosomal protein disease or disorder in a subject comprising:
 - isolating hematopoietic stem and progenitor cells (HSPCs) from bone marrow from the subject;
 - introducing a functional human lysosomal transmembrane gene into the HSPCs, wherein the gene encodes a protein corresponding to the lysosomal protein disease or disorder; and

transplanting the HSPCs back into the subject,
thereby treating or ameliorating the lysosomal protein disease or disorder.

24. The method of claim 23, wherein when:
 - (a) the lysosomal transmembrane protein disease or disorder is cystinosis, the functional human lysosomal transmembrane gene is CTNS;
 - (b) the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the functional human lysosomal transmembrane gene is SLC17A5;
 - (c) the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the functional human lysosomal transmembrane gene is LMBRD1;
 - (d) the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is MFSD8;
 - (e) the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is CLN3;
 - (f) the lysosomal transmembrane protein disease or disorder is malignant infantile osteopetrosis, the functional human lysosomal transmembrane gene is CLCN7 or OSTM1;
 - (g) the lysosomal transmembrane protein disease or disorder is mucopolidosis IV, the functional human lysosomal transmembrane gene is MCOLN1;
 - (h) the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the functional human lysosomal transmembrane gene is HGSNAT;
 - (i) the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the functional human lysosomal transmembrane gene is NPC1; and
 - (j) the lysosomal transmembrane protein disease or disorder is Danon disease, the functional human lysosomal transmembrane gene is LAMP2.
25. The method of claim 23, wherein the HSPCs are CD34+ cells.
26. The method of claim 24, wherein the lysosomal protein disease or disorder is cystinosis and the functional human lysosomal transmembrane gene is CTNS.

27. The method of claim 24, wherein the lysosomal protein disease or disorder is Danon disease and the functional human lysosomal transmembrane gene is LAMP2.
28. The method of claim 26, wherein the step of introducing the functional human CTNS gene into the HSPCs comprises using a vector.
29. The method of claim 28, wherein the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector.
30. The method of claim 29, wherein the vector is a lentiviral vector.
31. The method of claim 30, wherein the vector is a self-inactivating (SIN)-lentivirus vector.
32. The method of claim 26, wherein the level of cystine in the eye, skin, leukocytes, parenchymal tissue or gastrointestinal tract of the subject is reduced following treatment.
33. The method of claim 26, wherein the dosage is about 1.0×10^6 to 5.0×10^6 cells/kg.
34. The method of claim 33, wherein the dosage is about 2.5×10^6 cells/kg administered as a single dose.
35. The method of claim 26, wherein the subject has nephropathic cystinosis.
36. The method of claim 26, wherein the subject was on cysteamine therapy prior to treatment.
37. The method of claim 36, wherein the subject is on oral cysteamine therapy.
38. The method of claim 26, wherein administration is intravenous.

39. The method of claim 26, wherein cystine or cystine crystals are measured in the eye, skin, leukocytes, parenchymal tissue and/or gastrointestinal tract prior to and/or following treatment.
40. The method of claim 39, wherein cystine levels are measured prior to, during and/or following treatment.
41. The method of claim 39, wherein cystine levels are measured using biological samples.
42. The method of claim 41, wherein the biological samples are blood, rectal biopsies, or buccal mucosa.
43. The method of claim 39, wherein cystine crystals are measured using *in vivo* confocal microscopy.
44. A method of treating or ameliorating a lysosomal protein disease or disorder in a subject comprising:
 - producing a functional human lysosomal transmembrane gene in the subject using gene editing.
45. The method of claim 44, wherein when:
 - (a) the lysosomal transmembrane protein disease or disorder is cystinosis, the functional human lysosomal transmembrane gene is CTNS;
 - (b) the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the functional human lysosomal transmembrane gene is SLC17A5;
 - (c) the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the functional human lysosomal transmembrane gene is LMBRD1;
 - (d) the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is MFSD8;
 - (e) the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the functional human lysosomal transmembrane gene is CLN3;

- (f) the lysosomal transmembrane protein disease or disorder is malignant infantile osteopoetrosis, the functional human lysosomal transmembrane gene is CLCN7 or OSTM1;
 - (g) the lysosomal transmembrane protein disease or disorder is mucopolipidosis IV, the functional human lysosomal transmembrane gene is MCOLN1;
 - (h) the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the functional human lysosomal transmembrane gene is HGSNAT;
 - (i) the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the functional human lysosomal transmembrane gene is NPC1; and
 - (j) the lysosomal transmembrane protein disease or disorder is Danon disease, the functional human lysosomal transmembrane gene is LAMP2.
46. A method of treating or ameliorating a lysosomal protein disease or disorder in a subject comprising contacting cells expressing a defective lysosomal transmembrane protein from the subject with a vector encoding a gene editing system that, when transfected into the cells, removes a trinucleotide extension mutation of an endogenous gene encoding the lysosomal transmembrane protein, thereby treating the lysosomal protein disease or disorder.
47. The method of claim 46, wherein when:
- (a) the lysosomal transmembrane protein disease or disorder is cystinosis, the lysosomal transmembrane protein is cystinosin (CTNS);
 - (b) the lysosomal transmembrane protein disease or disorder is Salla disease or infantile sialic acid storage disorder, the lysosomal transmembrane protein is sialin (SLC17A5);
 - (c) the lysosomal transmembrane protein disease or disorder is Cobalamin F-type disease, the lysosomal transmembrane protein is LMBD1;
 - (d) the lysosomal transmembrane protein disease or disorder is late infantile neuronal ceroid lipofuscinosis, the lysosomal transmembrane protein is CLN7;
 - (e) the lysosomal transmembrane protein disease or disorder is juvenile neuronal ceroid lipofuscinosis, the lysosomal transmembrane protein is Battenin (CLN3);
 - (f) the lysosomal transmembrane protein disease or disorder is malignant infantile osteopoetrosis, the lysosomal transmembrane protein is ClC-7 or OSTM1;

- (g) the lysosomal transmembrane protein disease or disorder is mucopolipidosis IV, the lysosomal transmembrane protein is TRPML-1;
 - (h) the lysosomal transmembrane protein disease or disorder is mucopolysaccharidosis type IIC, the lysosomal transmembrane protein is HGSNAT;
 - (i) the lysosomal transmembrane protein disease or disorder is Neiman-Pick Type C, the lysosomal transmembrane protein is NPC-1; and
 - (j) the lysosomal transmembrane protein disease or disorder is Danon disease, the lysosomal transmembrane protein is LAMP2.
48. The method of claim 47, wherein the gene editing system is selected from the group consisting of CRISPR/Cas, zinc finger nucleases, and transcription activator-life effector nucleases.
49. The method of claim 47, wherein the step of contacting comprises administering to the subject an effective amount of the vector.
50. The method of claim 47, wherein the step of contacting comprises obtaining a sample of cells from the subject, transfecting the gene editing system into the sample of cells, and thereafter, transplanting the transfected cells into the subject.
51. The method of claim 46, wherein the sample of cells is selected from the group consisting of blood cells and HSPCs.

1/10


Ctns^{-/-} mice

FIG. 1A


Treated Ctns^{-/-} mice

FIG. 1B


Ctns^{-/-} mice

FIG. 1C


Treated Ctns^{-/-} mice

FIG. 1D

2/10




FIG. 2A




FIG. 2B

3/10




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7




FIG. 8A




FIG. 8B

Non-Treated Ctns^{-/-} mice




FIG. 8C

pCCL-CTNS-treated mice




FIG. 8D




FIG. 9A-1




FIG. 9A-2




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 11




FIG. 12A

10/10




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12D